Dual-targeting chimeric antigen receptors
Patent Information
- Application Number
- JP2023526252
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-10-30
- Filing Date
- 2021-10-29
- Publication Date
- 2024-11-07
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current CAR-T cell designs face challenges in maintaining structural integrity of antigen-binding moieties, achieving optimal T cell co-stimulation, and addressing tumor evasion due to antigen heterogeneity in solid tumors.
Development of dual-targeting chimeric antigen receptors (CARs) with split costimulatory signaling and a shared CD3ζ domain, specifically targeting GD2 and B7-H3 antigens, to enhance T cell activation and metabolic compatibility.
The dual-targeting CARs exhibit enhanced T cell activation, increased cytokine release, and improved tumor control, preventing tumor evasion and promoting sustained antitumor activity even under stress conditions.
Smart Images

Figure 00000057_0000 
Figure 00000057_0001 
Figure 00000057_0002
Abstract
Description
[Technical Field]
[0001] Cross-reference of related applications This application claims the benefits of U.S. Provisional Patent Application No. 63 / 108,047, filed on 30 October 2020. All teachings of the said application are incorporated herein by reference.
[0002] government support This invention was developed with the support of the U.S. government under grant numbers CA193140 and CA243543 granted by the National Institutes of Health. The U.S. government has certain rights to this invention. [Background technology]
[0003] Background of the Invention The development of successful CAR-T cell therapy in solid tumors presents key challenges, including the selection of appropriate targets to prevent off-tumor toxicity while remaining on-target, simultaneous recognition of multiple targets to prevent tumor evasion, and protection from the immunosuppressive tumor microenvironment. 1、2 .
[0004] Several antigen-targeted carcinomas (CARs) in solid tumors are currently in clinical trials, with the primary endpoint being to establish the safety of the selected antigen targets. 1 However, constructing next-generation CARs that simultaneously target at least two antigens, as well as defining the optimal method for including the cytoplasmic domain of the CAR, remains challenging. A single CAR cassette that dual-targets was generated by fusing the antigen-binding moiety to a single CAR stem that provides co-stimulation and CD3ζ signaling. 3~7 The main drawback of this design is the difficulty in maintaining the structural integrity of the aggregated antigen-binding region, which has an inherent tendency to unfold. 8Furthermore, T cell costimulation provided by either the CD28 endodomain or the 4-1BB endodomain is similarly effective in promoting clinical remission in patients with B cell malignancies. 9、10 However, there is a common understanding in the art that dual costimulation of CD28 and 4-1BB may promote rapid tumor regression maintained by CD28 and long-term persistence brought about by 4-1BB. 9、11、12 .
[0005] Optimal T cell costimulation is the first critically important event in counteracting immunosuppression within the tumor microenvironment of solid tumors. Multiple costimulations in CAR-T cells were achieved either by including two or three costimulatory endodomains in tandem (third-generation CAR) or by supplying the 4-1BB ligand to CAR-T cells encoding CD28. 13~16 However, the reported clinical data have not demonstrated a significant advantage with respect to the objective clinical response of third-generation CAR-T cells, suggesting that the in cis costimulatory endodomains cannot provide the spatial distribution of CD28 and 4-1BB costimulations required to promote optimal T cell activation and survival. 15、17、18 . SUMMARY OF THE INVENTION MEANS FOR SOLVING THE PROBLEM
[0006] SUMMARY OF THE INVENTION A dual-targeted, split costimulation signaling and shared CD3ζ chain approach tailored to the targeting of two clinically relevant antigens - GD2 and B7-H3 - in a neuroblastoma disease model is provided by the present disclosure. This design strategy has been demonstrated to achieve a rapid and sustained anti-tumor effect maintained by optimized signaling, effector molecule signature, and metabolic fitness of CAR-T cells. Furthermore, dual antigen targeting prevents tumor escape due to the heterogeneity of antigen expression in tumor cells. 19~21
[0007] Modified T cells are disclosed herein, and in some embodiments, the modified T cells include a splitting costimulatory signal and a dual-targeted CAR having a single CAR-CD3ζ domain.
[0008] In some embodiments, T cells co-stimulate CD28 and 4-1BB. In some embodiments, T cells express GD2 and B7-H3.
[0009] In some embodiments, T cells exhibit biantigen specificity and co-stimulation. In some embodiments, T cells exhibit T cell-killing activity and cytokine release by GD2.28ζ.CAR or B7-H3.BB.CAR. In some embodiments, T cells show increased IFN-γ and IL-2 release compared to control cells. In some embodiments, T cells show higher basal levels of TCR activation signaling compared to control cells. In some embodiments, T cells show enhanced phosphorylation of the CAR-CD3ζ chain and downstream signaling kinases, which may include ERK and Akt.
[0010] In some embodiments, T cells show enrichment in the cell cycle pathway, for example, 5 days after discontinuation of antigen stimulation. In some embodiments, T cells show enrichment in the TCR signaling pathway, for example, 5 days after discontinuation of antigen stimulation. In some embodiments, T cells show increased glycolytic activity compared to control cells, for example, on day 0 and day 5 after stimulation.
[0011] In some embodiments, T cells control tumor growth upon tumor re-administration compared to control cells. In some embodiments, T cells promote enhanced tumor control and improved survival compared to control cells. In some embodiments, T cells exhibit increased antitumor activity. In some embodiments, T cells exhibit increased antitumor activity under stress conditions.
[0012] In some embodiments, the T cells are human T cells. In some embodiments, the T cells are non-human T cells. In some embodiments, the T cells are mouse T cells.
[0013] Methods for treating cancer are also disclosed herein. The method includes the step of administering modified T cells containing a split-costimulatory signal and a dual-targeted CAR having a single CAR-CD3ζ domain to the target.
[0014] In some embodiments, T cells co-stimulate CD28 and 4-1BB. In some embodiments, T cells express GD2 and B7-H3. In some embodiments, modified T cells exhibit increased antitumor activity. In some embodiments, modified T cells protect against tumor re-administration.
[0015] In some embodiments, the cancer is neuroblastoma. In some embodiments, the subject is a mammal. In some embodiments, the subject is a human.
[0016] This patent or application file includes at least one drawing made in color. A copy of this patent or patent application publication accompanied by the color drawing will be provided by the United States Patent and Trademark Office upon request and payment of the necessary fees. [Brief explanation of the drawing]
[0017] [Figure 1A-C]Figures 1A–1H demonstrate that single or dual antigen targeting and single or dual CD28 or 4-1BB co-stimulation do not eradicate tumors under stress conditions. Figure 1A shows a scheme of the CHLA-255 metastatic xenograft NB model in NSG mice inoculated intravenously via the tail vein with FFLuc-labeled CHLA-255 cells and treated 14 days later with low-dose CAR-T cells targeting either GD2 or B7-H3. Figures 1B–1C provide representative tumor bioluminescence (BLI) images (Figure 1B) and BLI dynamics (Figure 1C) of FFLuc-CHLA-255 tumor growth in the metastatic xenograft NB model (mice n=5 / group) shown in Figure 1A. Figure 1D provides Kaplan-Meier survival curves for the mice (mice n=5 / group) in Figures 1B–1C. By chi-square test, **p<0.01. Figure 1E shows a scheme for a CHLA-255 metastatic xenograft NB model in NSG mice that were intravenously inoculated via the tail vein with FFLuc-labeled CHLA-255 cells and, 14 days later, administered low doses of CAR-T cells targeting either GD2 or both GD2 and B7-H3. Figures 1F-1G provide representative tumor BLI (Figure 1F) and BLI dynamics (Figure 1G) for FFLuc-CHLA-255 tumor growth in the metastatic xenograft NB model (mouse n=4 or 5 / group) shown in Figure 1E. Figure 1H provides Kaplan-Meier survival curves for the mice (mouse n=4 or 5 / group) in Figures 1F-1G. Chi-square test shows **p<0.01. [Figure 1E-F] Same as above. [Figure 1G-H] Same as above. [Figure 2A-G]Figures 2A–2Q demonstrate that dual targeting, fragmentation signaling, and a single CD3ζ endodomain promote a sustained T cell activation profile without inducing T cell fatigue. Figure 2A provides a representative flow cytometry histogram showing CAR expression in human T cells transduced with retroviral vectors encoding CD19.28ζ.CAR, GD2.28ζ.CAR, or GD2.28ζ.CAR / B7-H3.BB.CAR. Figure 2B provides a summary of the transduction efficiency (n=13) of CD19.28ζ.CAR, GD2.28ζ.CAR, or GD2.28ζ.CAR / B7-H3.BB.CAR. Horizontal bars represent mean values. Figure 2C shows a scheme of repeated co-culture experiments of CAR-T cell and NB cell lines. Tumor cells were seeded in 24-well plates the day before T cell addition. On day 0, CAR-T cells were added in a T cell to tumor cell ratio of 1:5. On days 4, 6, and 8, all T cells were collected and transferred to new wells seeded the day before T cell addition with 5 × 10⁵ NB cells. T cells and NB cells were quantified by flow cytometry after each cycle. The supernatant was also collected 24 hours after T cell addition each cycle for cytokine measurement. Figures 2D–2E show the quantification of residual CHLA-255 cells (Figure 2D) and T cell counting (Figure 2E) in repeated co-culture. Error bars indicate SE. n=12. One-way ANOVA with p-value correction using Tukey multiple comparison test showed ***p<0.001, ns (not significant). Figures 2F–2G provide a summary of IFN-γ (Figure 2F) and IL-2 (Figure 2G) released by CAR-T cells in the culture supernatant after 24 hours of co-culture with CHLA-255, as measured by ELISA. Error bars indicate SE. n=12. One-way ANOVA with p-value correction using Tukey multiple comparison test showed ***p<0.001. Figures 2H-2I show the quantification of residual LAN-1 cells (Figure 2H) and counting of T cells (Figure 2I) in repeated co-culture experiments. Error bars indicate SE. n=12. One-way ANOVA with p-value correction using Tukey multiple comparison test showed **p<0.01, ***p<0.001, ns (not significant).Figures 2J–2K provide a summary of IFN-γ (Figure 2J) and IL-2 (Figure 2K) released by CAR-T cells in the culture supernatant after 24 hours of co-culture with LAN-1, as measured by ELISA. Error bars indicate SE. n=12. One-way ANOVA with p-value correction by Tukey multiple comparison test yielded **p<0.01, ***p<0.001. Figure 2L shows a scheme of the CHLA-255 metastatic xenograft NB model in NSG mice inoculated intravenously via the tail vein with FFLuc-labeled CHLA-255 cells and treated 14 days later with low-dose CAR-T cells targeting either GD2 or GD2 and B7-H3. Figures 2M–2N provide representative tumor BLI images (Figure 2M) and BLI dynamics (Figure 2N) of FFLuc-CHLA-255 tumor growth in the metastatic xenograft NB model (mouse n=5 / group) shown in Figure 2L. Figure 2O shows the Kaplan-Meier survival curves for mice (n=5 / group) in Figures 2M-2N. Chi-square test shows p<0.01. Figures 2P-2Q show the detection of circulating CAR-T cells (CD45+CD3+) by flow cytometry in mice (n=3-5 / group) 14 days (Figure 2P) and 28 days (Figure 2Q) after CAR-T cell treatment. One-way ANOVA with p-value correction using Tukey multiple comparison test, or unpaired t-test, shows p<0.05, ns (not significant). [Figure 2H-L] Same as above. [Figure 2M-N] Same as above. [Figure 2O-Q] Same as above. [Figure 3A-D]Figures 3A–3M demonstrate that dual targeting, fragmentation signaling, and a single CD3ζ endodomain promote TCR tonic signaling and both glycolytic and oxidative metabolism. Figure 3A shows RNA-seq analysis of unstimulated CAR-T cells. Figures 3B–3D provide gene set enrichment analysis (GSEA) of glycolysis (Figure 3B), IFN-γ signaling pathways (Figure 3C), and TCR upregulatory genes (Figure 3D) in unstimulated T cells expressing GD2.28ζ.CAR or GD2.28ζ.CAR / B7-H3.BB.CAR. Figures 3E–3H show RNA-seq analysis of GD2.28ζ.CAR-T cells and GD2.28ζ.CAR / B7-H3.BB.CAR-T cells at day 1 (Figure 3E) and day 5 (Figure 3F) after CAR stimulation. Figures 3G–3H show the GSEA of the cell cycle (Figure 3G) and TCR (Figure 3H) signaling 5 days after CAR stimulation. Figure 3I shows the principal component analysis of transcriptome data from CAR-T cells on days 0, 1, and 5. Figures 3J–3K show the proliferation of CAR-T cells after CAR stimulation. Figure 3J shows that CAR-T cells were stained with CFSE, then stimulated with 1A7 Ab and B7-H3-Fc proteins on day 0, and CFSE dilution was examined by flow cytometry on days 3 and 6 post-stimulation. Cell count (Figure 3K) was counted by flow cytometry using counting beads in a separate experiment without CFSE staining (n=5, *p=0.0283). Figures 3L–3M provide metabolic profiles showing glucose (Figure 3L) and O2 consumption (Figure 3M) of GD2.28ζ.CAR-T cells and GD2.28ζ.CAR / B7-H3BB.CAR-T cells before CAR activation (resting) and on days 1 and 5 after CAR activation. Extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) were assayed at different time points using a Seahorse XF24 analyzer (n=3, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001). Long and short arrows indicate the time points at which Rot / AA and 2-DG were added, respectively (Figure 3L), and black, green, and purple arrows indicate the time points at which oligomycin, FCCP, and Rot / AA were added, respectively (Figure 3M). [Figure 3E-H]Same as above. [Figure 3I-K] Same as above. [Figure 3L-M] Same as above. [Figure 4A-E] Figures 4A–4I demonstrate that dual targeting, fragmentation signaling, and a single CD3ζ endodomain prevent tumor evasion due to antigen deficiency. Figure 4A provides flow cytometry histograms showing GD2 and B7-H3 expression in stained human NB cell lineage SH-SY5Y. Figure 4B shows quantification of GFP-labeled residual NB cells co-cultured with CAR-T cells at a 1:5 T cell-to-tumor cell ratio. On day 5, NB cells (GFP+) and CAR-T cells (CD3+) were counted by flow cytometry. Error bars indicate SE. n=10. One-way ANOVA with p-value correction using Tukey multiple comparison test showed *p<0.05, ***p<0.001. Figures 4C–4D show a summary of IFN-γ (Figure 4C) and IL-2 (Figure 4D) released by CAR-T cells in the culture supernatant after 24 hours of co-culture with NB cells, as measured by ELISA. Error bars indicate SE. n=10. By one-way ANOVA with p-value correction using Tukey multiple comparison tests, *p<0.05, **p<0.01, ***p<0.001. Figure 4E shows the scheme of the SH-SY5Y metastatic xenograft NB model in NSG mice inoculated intravenously via the tail vein with 5 × 10⁵ FFLuc-SH-SY5Y cells and treated with intravenous injection of 10 × 10⁶ CAR-T cells 7 days later. Figures 4F-4G provide representative tumor BLI images (Figure 4F) and BLI dynamics (Figure 4G) of FFLuc-SH-SY5Y tumor growth in the metastatic xenograft NB model (mouse n=4 or 5 / group) shown in Figure 4E. Figure 4H shows the Kaplan-Meier survival curves for mice (mouse n=4 or 5 / group) in Figures 4F-4G. By chi-square test, *p<0.05. Figure 4I shows the GD2 and B7-H3 expression levels of tumor cells in CD19.CAR and GD2.CAR-T cell-treated mice, analyzed by flow cytometry at the time of euthanasia. [Figure 4F] Same as above. [Figure 4G-I] Same as above. [Figure 5A-B] Figures 5A–5H demonstrate that GD2.CAR and B7-H3.CAR-T cells target neuroblastoma in vitro. Figure 5A provides flow cytometry histograms showing GD2 expression in two human NB cell lines, CHLA-255 and LAN-1. Figure 5B provides representative flow cytometry histograms showing CAR expression in human T cells transduced with retroviral vectors encoding CD19.28ζ, GD2.28ζ, GD2.BBζ, B7-H3.28ζ, and B7-H3.BBζ. Figures 5C–5E provide representative flow cytometry plots (Figure 5C) of GFP-labeled residual CHLA-255 cells and LAN-1 cells co-cultured with CAR-T cells at a 1:5 T-cell to tumor cell ratio, as well as quantifications of residual CHLA-255 cells (Figure 5D) and LAN-1 cells (Figure 5E). On day 5, NB cells (GFP+) and CAR-T cells (CD3+) were counted by flow cytometry. Error bars indicate non-significant (SE). n=6. One-way ANOVA with p-value correction using Tukey multiple comparison test was ns (not significant). Figures 5F-5G show a summary of IFN-γ (Figure 5F) and IL-2 (Figure 5G) released by CAR-T cells in the culture supernatant after 24 hours of co-culture with NB cells, as measured by ELISA. Error bars indicate non-significant (SE). n=6. One-way ANOVA with p-value correction using Tukey multiple comparison test was ns (not significant). Figure 5H shows representative CFSE dilutions (red histogram) of CSFE-labeled CAR-T cells co-cultured with NB cells for 5 days at a 1:1 T cell-to-tumor cell ratio. CFSE-labeled CAR-T cells alone (gray histogram) were used as a negative control. [Figure 5C-E] Same as above. [Figure 5F-H] Same as above. [Figure 6A-B]Figures 6A–6D demonstrate that high doses of GD2.CAR-T and B7-H3.CAR-T co-stimulated with either CD28 or 4-1BB equally control tumor growth in vivo. Figure 6A provides a scheme for a CHLA-255 metastatic xenograft NB model using NSG mice inoculated intravenously via the tail vein with 2 × 10⁶ FFluc-CHLA-255 cells, followed by intravenous administration of a high dose of CAR-T (6 × 10⁶ cells / mouse) 14 days later. Figures 6B–6C provide bioluminescence images (Figure 6B) and bioluminescence dynamics (Figure 6C) of FFluc-CHLA-255 tumor growth (mice n=5 / group) in the metastatic xenograft NB model shown in (Figure 6A). Figure 6D provides Kaplan-Meier survival curves for mice (mice n=5 / group) in (Figures 6B–6C). [Figure 6C-D] Same as above. [Figure 7A-B] Figures 7A–7D demonstrate that GD2.28ζ.CAR-T exhibits the strongest antitumor activity between GD2.CAR-T and B7-H3.CAR-T in vivo. Figure 7A shows a scheme for a LAN-1 metastatic xenograft NB model using NSG mice that were intravenously inoculated with FFLuc-LAN-1 cells via the tail vein and intravenously administered a low dose of CAR-T targeting either GD2 or B7-H3 21 days later. Figures 7B–7C provide bioluminescence images (Figure 7B) and dynamics (Figure 7C) of FFLuc-LAN-1 tumor growth (mice n=3 / group). Figure 7D shows Kaplan-Meier survival curves for mice (mice n=3 / group) in Figures 7B–7C. [Figure 7C-D] Same as above. [Figure 8A-B]Figures 8A–8E demonstrate that tandem addition of 4-1BB and simple addition of B7-H3.BBζ do not improve the antitumor activity of GD2.28ζ.CAR-T cells in vitro. Figure 8A provides representative flow cytometry histograms showing CAR expression in human T cells transduced with retroviral vectors encoding CARs CD19.28ζ, GD2.28ζ, GD2.28.BBζ, or GD2.28ζ / B7-H3.28ζ. Figures 8B–8C provide representative flow cytometry plots (Figure 8B) and quantification of residual CHLA-255 cells (Figure 8C) co-cultured with CAR-T cells at a 1:5 T-cell to tumor cell ratio of GFP. Error bars indicate SE. n=6. One-way ANOVA with p-value correction using Tukey multiple comparison tests showed *p<0.05, **p<0.01, ***p<0.001, ns (not significant). Figures 8D-8E show a summary of IFN-γ (Figure 8D) and IL-2 (Figure 8E) released by CAR-T in the culture supernatant after 24 hours of co-culture with NB cells, as measured by ELISA. Error bars indicate SE. n=6. One-way ANOVA with p-value correction using Tukey multiple comparison tests showed *p<0.05, **p<0.01, ***p<0.001, ns (not significant). [Figure 8C-E] Same as above. [Figure 9A-B]Figures 9A–9E demonstrate that a single covalent CD3ζ chain is sufficient for the transmission of the activation signal in bispecific CAR-T cells. Figure 9A shows schematic diagrams of retroviral vectors encoding B7-H3.BB, B7-H3.BBζ, GD2.28ζ, GD2.28ζ / B7-H3.BB, dNGFR.28ζ / B7-H3.BB, and 28ζ / B7-H3.BB. Figures 9B–9C provide representative flow cytometry plots (Figure 9B) and percentages of residual GFP-labeled CHLA-255 cells (Figure 9C) in co-culture experiments seeded with CAR-T cells and tumor cells in a 1:5 T-cell to tumor cell ratio. Error bars indicate SE. n=4. One-way ANOVA with p-value correction using Tukey multiple comparison test, ns (not significant). Figures 9D–9E summarize the levels of IFN-γ (Figure 9D) and IL-2 (Figure 9E) released by CAR-T cells in the culture supernatant after 24 hours of co-culture with NB cells, as measured by ELISA. Error bars indicate SE. n=4. One-way ANOVA with p-value correction using Tukey multiple comparison test showed *p<0.05 and ***p<0.001. [Figure 9C-E] Same as above. [Figure 10] Figures 10A–10B demonstrate the memory phenotype after 13 days of expansion in vitro. Figures 10A–10B show the phenotypic characteristics of human T cells transduced with retroviral vectors encoding GD2.28ζ.CAR or GD2.28ζ / B7-H3.BB.CAR. Frequencies of CD45RA+CCR7+, CD45RA-CCR7+, CCR7-CD28+CD27+, CCR7-CD28+CD27-, CCR7-CD28-CD27+, and CCR7-CD28-CD27- in CD4+ (Figure 10A) and CD8+ (Figure 10B) T cells 13 days post-transduction. Error bars indicate SE. n=4. [Figure 11A-B]Figures 11A–11D demonstrate the phenotypic characteristics of CAR-T cells in vivo. Figures 11A–11B show the phenotypic characteristics of human T cells transduced with retroviral vectors encoding GD2.28ζ.CAR or GD2.28ζ.CAR / B7-H3.BB.CAR. Frequencies of CD45RA+CCR7+, CD45RA-CCR7+, CCR7-CD28+CD27+, CCR7-CD28+CD27-, CCR7-CD28-CD27+, and CCR7-CD28-CD27- in CD4+ (Figure 11A) and CD8+ (Figure 11B) T cells 14 days after CAR-T treatment. Error bars indicate SE. n=5. Figures 11C–11D show the mean fluorescence intensities of PD-1 (Figure 11C) and TIM-3 (Figure 11D) in human T cells transduced with retroviral vectors encoding GD2.28ζ.CAR or GD2.28ζ.CAR / B7-H3.BB.CAR 14 days after CAR-T treatment. Error bars indicate set-off (SE). n=5. Unpaired t-tests showed *p<0.05 and ***p<0.001. [Figure 11C-D] Same as above. [Figure 12A-C]Figures 12A–12F demonstrate that dual targeting, fragmentation signaling, and a single CD3ζ endodomain promote TCR tonic signaling. Figures 12A–12C show the scheme for CAR-T cell stimulation and sample preparation for RNA-seq (Figure 12A). Both GD2.28ζ.CAR-T cells and GD2.28ζ.CAR / B7-H3.BB.CAR-T cells were stimulated with 1 μg / mL 1A7 antibody and 1 μg / mL B7-H3-Fc protein coated plates, and CAR-T cells were collected for RNA-seq on days 0, 1, and 5 post-stimulation. Gene set enrichment analysis (GSEA) (Figure 12B) and qPCR validation (Figure 12C) of upregulated and downregulated TCR-related genes in GD2.28ζ.CAR-T cells compared to GD2.28ζ.CAR / B7-H3.BB.CAR-T cells in the absence of antigen stimulation. Figure 12D shows the basal phosphorylation of CAR-CD3ζ, Erk1 / 2, and Akt in GD2.28ζ.CAR-T cells and GD2.28ζ.CAR / B7-H3.BB.CAR-T cells in the absence of antigen stimulation. Figure 12E shows the time course of CAR-CD3ζ, Erk1 / 2, and Akt phosphorylation in GD2.28ζ.CAR-T cells and GD2.28ζ.CAR / B7-H3.BB.CAR-T cells after CAR crosslinking (1A7 Ab for GD2.CAR and B7-H3-Fc protein for B7-H3.CAR). Figure 12F shows the KEGG pathway analysis of the top 100 loading genes of PC2 in Figure 3I. [Figure 12D-F] Same as above. [Figure 13A-B]Figures 13A–13D demonstrate that GD2.28ζ.CAR / B7-H3.BB.CAR-T cells exhibit superior antitumor efficacy and prevent antigen evasion when targeting neuroblast tumors heterogeneously expressing GD2 in a high tumor-burdened xenograft model. Figure 13A shows a scheme for a high tumor-burdened SH-SY5Y metastatic xenograft NB model using NSG mice inoculated intravenously via the tail vein with 1 × 10⁶ FFLuc-SH-SY5Y cells, followed by intravenous administration of 10 × 10⁶ CAR-T cells 7 days later. Figures 13B–13C provide bioluminescence images (Figure 13B) and bioluminescence dynamics (Figure 13C) of FFLuc-SH-SY5Y tumor growth (mice n=5 / group) in the metastatic xenograft NB model shown in Figure 13A. Figure 13D shows Kaplan-Meier survival curves for mice (mice n=5 / group) in Figures 13B–13C. [Figure 13C-D] Same as above. [Figure 14A-B]Figures 14–32 re-present certain data from Figures 1–13 and provide additional data. Figures 14A–14H demonstrate that single or dual antigen targeting and single or dual CD28 or 4-1BB costimulation do not eradicate tumors under stress conditions. Figure 14A provides a scheme for a CHLA-255 metastatic xenograft NB model in NSG mice inoculated by tail injection with FFLuc-labeled CHLA-255 cells and treated 14 days later with low-dose CAR-T cells targeting either GD2 (GD2.28ζ and GD2.BBζ) or B7-H3 (B7-H3.28ζ and B7-H3.BBζ) or control CD19.28ζ. Figures 14B–14C provide representative tumor bioluminescence (BLI) images (Figure 14B) and BLI dynamics (Figure 14C) of FFLuc-CHLA-255 tumor growth in the metastatic xenograft NB model (mice n=5 / group) shown in Figure 14A. Figure 14D shows the Kaplan-Meier survival curves for mice (mice n=5 / group) in Figures 14B–14C. Comparison of survival curves was determined by the log-rank test. **p=0.0027** for CD19.28ζ compared to all other groups. **p=0.0027** for GD2.28ζ compared to B7-H3.BBζ, for GD2.BBζ compared to B7-H3.BBζ, and for B7-H3.BBζ compared to B7-H3.28ζ. **p=0.0018** for GD2.28ζ against GD2.BBζ, and for GD2.28ζ against B7-H3.28ζ. **p=0.0018** for GD2.BBζ against B7-H3.28ζ. Figure 14E provides a scheme for a CHLA-255 metastatic xenograft NB model in NSG mice inoculated by tail vein injection with FFLuc-labeled CHLA-255 cells and treated 14 days later with low doses of GD2.28ζ, GD2.28.BBζ, GD2.28ζ / B7-H3.BBζ, and control CD19.28ζ CAR-T cells. Figures 14F-14G show representative tumor BLI (Figure 14F) and BLI dynamics (Figure 14G) of FFLuc-CHLA-255 tumor growth in the metastatic xenograft NB model (mouse n=4 or 5 / group) shown in Figure 14E.Figure 14H shows the Kaplan-Meier survival curves for mice (n=4 or 5 mice / group) in Figures 14F-14G. Comparison of survival curves was determined by the log-rank test. **p=0.0072 for CD19.28ζ over GD2.28ζ. **p=0.0027 for CD19.28ζ over GD2.28.BBζ, and for CD19.28ζ over GD2.28ζ / B7-H3.BBζ. *p=0.0350 for GD2.28ζ over GD2.28ζ / B7-H3.BBζ. *p=0.0157 for GD2.28.BBζ over GD2.28ζ / B7-H3.BBζ. [Figure 14C-D] Same as above. [Figure 14E-F] Same as above. [Figure 14G-H] Same as above. [Figure 15A-B]Figures 15A–15E demonstrate that a single covalent CD3ζ chain is sufficient for the transmission of activation signals in bispecific CAR-T cells. Figure 15A provides a schematic diagram of retroviral vectors encoding B7-H3.BB, B7-H3.BBζ, GD2.28ζ, 28ζ, dNGFR.28ζ, GD2.28ζ / B7-H3.BB, GD2.28ζ / dNGFR.BB, dNGFR.28ζ / B7-H3.BB, and 28ζ / B7-H3.BB. scFv.14.g2a is a single-chain variable fragment of the anti-GD2 monoclonal antibody 14.g2a, scFv.276.96 is a single-chain variable fragment of the anti-B7-H3 monoclonal antibody 376.96, CD8α is the stalk and transmembrane region of human CD8α, CD28 is the intracellular domain of human CD28, 4-1BB is the intracellular domain of human 4-1BB, CD3ζ is the intracellular domain of the human CD3ζ chain, and dNGFR is the extracellular domain of the human nerve growth factor receptor. Figure 15B shows a representative flow cytometry plot of residual GFP-labeled CHLA-255 cells in a co-culture experiment in which CAR-T cells and tumor cells were seeded at a T cell-to-tumor cell ratio of 1:5, and tumor cells (GFP+) and T cells (CD3+) were counted by flow cytometry on day 5 after co-culture. Representative of four independent experiments. Figures 15C–15E provide a summary of residual tumor cells (Figure 15C), IFN-γ (Figure 15D), and IL-2 (Figure 15E) released by CAR-T cells in the co-culture experiment described in Figure 15B. NTs are non-transduced T cells, and data are shown as individual values and mean + SD. For the NT and dNGFR.28ζ / B7-H3.BB groups, independent co-culture with CAR-T cells generated from four different donors (n=4) was performed, and for the other groups, independent co-culture with CAR-T cells generated from six different donors (n=6). In Figure 15E, *p=0.0119. In Figure 15D, **p=0.0027** for GD2.28ζ / B7-H3.BB relative to GD2.28ζ / dNGFR.BB, and **p=0.0051** for GD2.28ζ / B7-H3.BB relative to 28ζ / B7-H3.BB.In Figure 15D, ***p=0.0002 for B7-H3.BBζ relative to GD2.28ζ / B7-H3.BB, and ***p=0.0005 for GD2.28ζ relative to GD2.28ζ / B7-H3.BB. In Figure 15E, ***p=0.0001. In Figures 15C to 15E, ****p<0.0001. These results were obtained using one-way ANOVA with p-value correction using Tukey multiple comparison tests. [Figure 15C-E] Same as above. [Figure 16A-C]Figures 16A–16G demonstrate that CD3ζ co-shading in bilayer CARs relies on CD8α-mediated dimerization. Figures 16A–16B show that T cells co-expressing B7-H3.BB and dNGFR.28ζ or 28ζ were stimulated with B7-H3-Fc protein and subsequently incubated with anti-Fc secondary Ab at 37°C for 20 minutes. The cells were then lysed at 100°C for 10 minutes under non-reducing (without β-mercaptoethanol) (Figure 16A) or reducing (with β-mercaptoethanol) (Figure 16B) conditions with Laemmli buffer and separated on non-reducing or reducing gels. The membranes were stained with anti-CD3ζ antibody. The data are representative of two independent experiments in Figures 16A–16B. Figure 16C provides a schematic diagram of the retroviral vector encoding dNGFR.28ζ / B7-H3.BB(CD8m) and 28ζ / B7-H3.BB(CD8m). CD8m is the stalk and transmembrane region of human CD8α with C164S and C181S mutations. Figures 16D–16F provide summaries of residual tumor cells (Figure 16D), IFN-γ (Figure 16E), and IL-2 (Figure 16F) in co-culture experiments with CAR-T cells and CHLA-255 at a 1:5 T cell-to-tumor cell ratio. Data are shown as individual values and mean + SD. Independent co-culture with CAR-T cells generated from four different donors n=4. One-way ANOVA with p-value correction in Tukey multiple comparison test showed ****p<0.0001. Figure 1G shows representative confocal microscopy images illustrating CAR clustering in T cells expressing GFP-tagged GD2.28ζ (green) and B7-H3.BB (red), with or without CAR association, using either the anti-14g2a idiotype antibody (1A7) or the B7-H3-Fc protein. Blue staining indicates DAPI. Representative cells are shown. Data are representative of three independent validations. White indicates a scale bar corresponding to 5 μm. [Figure 16D-F] Same as above. [Figure 16G] Same as above. [Figure 17A-C]Figures 17A–17Q demonstrate that dual targeting with fractional costimulation and shared single CD3ζ promotes sustained antitumor activity. Figure 17A provides a representative flow cytometry plot showing CAR expression in CAR-T cells. Figure 17B provides a summary of CAR transduction efficiency (independent experiment n=9), where data are shown as individual values and mean + SD. Figure 17C provides a scheme for a multi-round co-culture experiment. Tumor cells were seeded in 24-well plates the day before T cell addition. On day 0, CAR-T cells were added at a T cell to tumor cell ratio of 1:5. On days 4, 6, and 8, all T cells were collected and transferred to new wells seeded the previous day with 5 × 10⁵ NB cells. T cells and NB cells were quantified by flow cytometry after each cycle. Supernatants were also collected 24 hours after T cell addition for cytokine measurement each cycle. Figures 17D–17K show multi-round co-culture experiments with CHLA-255 (Figures 17D–17G) and LAN-1 (Figures 17H–17K) cells. Summary of quantification of residual tumor cells (Figures 17D, 17H), T cell counting (Figures 17E, 17I), and IFN-γ (Figures 17F, 17J) and IL-2 (Figures 17G, 17K) released by CAR-T cells in the multi-round co-culture experiments. Data are presented as individual values and mean + SD. Independent co-culture with CAR-T cells generated from 12 different donors (n=12). One-way ANOVA with p-value correction using Tukey multiple comparison tests yielded *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. A complete list of p-values is available from the source data. Figure 17L provides a scheme for a CHLA-255 metastatic xenograft NB model. Figures 17M-17N show representative tumor BLI images (Figure 17M) and BLI dynamics (Figure 17N) of FFLuc-CHLA-255 tumor growth in the tumor model (mice n=5 / group) shown in (Figure 17L). Figure 17O shows Kaplan-Meier survival curves for mice (mice n=5 / group) in (Figures 17M-17N). By log-rank test, **p<0.01.Figures 17P–17Q provide a summary of circulating CAR-T cells (CD45+CD3+) in mice 14 days (Figure 17P) and 28 days (Figure 17Q) after CAR-T cell treatment (n=3 mice in the GD2.28ζ group in Figure 17Q, n=5 mice per group in the other groups), with data presented as individual values and mean + SD. In Figure 17P, **p=0.0038** for CD19.28ζ compared to GD2.28ζ / B7-H3.BB, and **p=0.0044** for GD2.28ζ compared to GD2.28ζ / B7-H3.BB. These are p-values corrected by one-way ANOVA with Tukey's test for multiple comparisons. [Figure 17D-G] Same as above. [Figure 17H-K] Same as above. [Figure 17L-M] Same as above. [Figure 17N-Q] Same as above. [Figure 18A-B]Figures 18A–18I demonstrate that MSLN and CSPG4 dual-targeted CAR-T cells with split-costimulation and co-CD3ζ exhibit sustained T cell activation and proliferation in vitro and in vivo. Figure 18A provides a schematic diagram of retroviral vectors encoding CSPG4.BB, CSPG4.BBζ, MSLN.28ζ, and MSLN.28ζ / CSPG4.BB CARs. scFv.763.74 is a single-stranded variable fragment of the anti-CSPG4 monoclonal antibody 763.74, amatsuximab is a single-stranded variable fragment of the anti-MSLN monoclonal antibody amatsuximab, CD8α is the stalk and transmembrane region of human CD8α, CD28 is the intracellular domain of human CD28, 4-1BB is the intracellular domain of human 4-1BB, CD3ζ is the intracellular domain of the human CD3ζ chain, and F is the Flag tag. Figure 18B provides flow cytometry histograms showing the expression of MSLN and CSPG4 in the human mesothelioma cell line H2052. Representatives from three independent experiments. Figures 18C–18D provide a summary of the number of residual H2052 cells (Figure 18C) and T cells (Figure 18D) in multi-round co-culture experiments with H2052 tumor cells. Data are shown as individual values and mean + SD. For the CSPG4.BBζ group, there were n=3 independent experiments with CAR-T cells generated from three different donors; for the other groups, there were n=4 independent experiments with CAR-T cells generated from four different donors. One-way ANOVA with p-value correction using Tukey multiple comparison tests yielded *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. A complete list of p-values is available from the source data. Figure 18E shows a scheme of the H2052 intraperitoneal xenograft model in NSG mice. 8-10 week old female NSG mice were inoculated with 3 × 10⁶ FFLuc-labeled H2052 cells by intraperitoneal injection, and 12 days later, they were treated with 2 × 10⁶ CD19.28ζ, CSPG4.BBζ, MSLN.28ζ, or MSLN.28ζ / CSPG4.BB CAR-T cells by intraperitoneal injection.Figures 18F–18G show representative tumor BLI images (Figure 18F) and BLI dynamics (Figure 18G) of FFLuc-H2052 tumor growth in the mesothelioma xenograft model shown in Figure 18A. Figure 18H shows Kaplan-Meier survival curves for mice in Figures 18F–18G, n=6 for the CD19.28ζ group and n=8 for the other groups. Log-rank tests show ***p=0.0003 and ****p<0.0001. Figure 18I shows flow cytometry detection of circulating CAR-T cells (CD45+CD3+) 19 days after CAR-T cell treatment, with data shown as individual values and mean + SD. n=6 for the CD19.28ζ group and n=8 for the other groups. One-way ANOVA with p-value correction using Tukey multiple comparison tests showed *p<0.05 (0.0103 for CSPG4.BBζ relative to Co, and 0.0159 for MSLN.28ζ relative to Co), **p=0.0084. [Figure 18C-D] Same as above. [Figure 18E-F] Same as above. [Figure 18G-I] Same as above. [Figure 19A-F]Figures 19A–19I demonstrate that dual targeting with split co-stimulation and co-dependency D3ζ promotes TCR tonic signaling. Figure 19A shows the scheme for CAR-T cell stimulation and sample preparation for RNA sequencing. Both GD2.28ζ and GD2.28ζ / B7-H3.BB CAR-T cells were stimulated for 24 hours on plates coated with 1 μg / mL 1A7 Ab and 1 μg / mL B7-H3-Fc proteins, then transferred to fresh, uncoated plates and cultured for a further 4 days. CAR-T cells were collected for RNA sequencing on days 0, 1, and 5. Figure 19B provides RNA sequencing analysis of unstimulated GD2.28ζ and GD2.28ζ / B7-H3.BB CAR-T cells. Figures 19C–19F show gene set enrichment analyses (GSEA) of glycolysis (Figure 19C), IFN-γ signaling pathways (Figure 19D), and TCR upregulation (Figure 19E) and downregulation (Figure 19F) genes in unstimulated CAR-T cells expressing GD2.28ζ or GD2.28ζ / B7-H3.BB. Figure 19G shows qPCR validation of upregulation and downregulation of TCR-related genes in GD2.28ζ CAR-T cells compared to GD2.28ζ / B7-H3.BB CAR-T cells in the absence of antigen stimulation. Independent donor n=4. Data are shown as individual values and mean + SD in C. *p<0.05, **p<0.01. These are two-sided p-values determined by unpaired t-tests. Figure 19H shows the basal phosphorylation of CAR-CD3ζ, Erk1 / 2, and Akt in GD2.28ζ and GD2.28ζ / B7-H3.BB.CAR-T cells in the absence of antigen stimulation. The data is from one experiment representative of three independent experiments. Figure 19I shows the time course of CAR-CD3ζ, Erk1 / 2, and Akt phosphorylation in GD2.28ζ and GD2.28ζ / B7-H3.BB CAR-T cells after CAR crosslinking (1A7 Ab for GD2.CAR and B7-H3-Fc protein for B7-H3.CAR). The data is from one experiment representative of three independent experiments. [Figure 19G] Same as above. [Figure 19H-I] Same as above. [Figure 20A-D]Figures 20A–20I demonstrate that dual targeting with split co-stimulation and shared CD3ζ promotes CAR-T cell proliferation, as well as glycolysis and oxidative metabolism. Figures 20A–20B show RNA-seq analyses of GD2.28ζ and GD2.28ζ / B7-H3.BB CAR-T cells at day 1 (Figure 20A) and day 5 (Figure 20B) after CAR stimulation. Figures 20C–20D show GSEA of cell cycle (Figure 20C) and TCR (Figure 20D) signaling at 5 days after CAR stimulation. Figure 20E shows principal component analysis of transcriptome data from GD2.28ζ and GD2.28ζ / B7-H3.BB CAR-T cells at days 0, 1, and 5. Figures 20F–20G show the proliferation of GD2.28ζ and GD2.28ζ / B7-H3.BB CAR-T cells after CAR stimulation. Figure 20F shows that CAR-T cells were stained with CFSE, then stimulated with 1A7 Ab and B7-H3-Fc proteins on day 0, and CFSE dilution was examined by flow cytometry on days 3 and 6 post-stimulation. Representative of four independent experiments. Figure 20G shows that T cell counts were counted by flow cytometry using counting beads in another experiment without CFSE staining (independent experiment n=5 with CAR-T cells generated from 5 different donors). Error bars indicate SD. *p<0.0001. This was determined by unpaired multiple t-tests with Holm-Sidak correction for multiple comparisons. Figures 20H–20I provide metabolic profiles showing glucose (Figure 20H) and O2 consumption (Figure 20I) of GD2.28ζ and GD2.28ζ / B7-H3BB CAR-T cells before CAR activation (resting) and at days 1 and 5 after CAR activation. Extracellular acidification rate (ECAR) and O2 consumption rate (OCR) were assayed at different time points in independent experiments (n=3) using a Seahorse XF24 analyzer. Error bars indicate SD. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, two-way ANOVA with Sidak correction for multiple comparisons. A complete list of p-values is available from the source data.The long and short arrows indicate the time points when Rot / AA and 2-DG were added, respectively (Figure 20H), while the black, green, and purple arrows indicate the time points when oligomycin, FCCP, and Rot / AA were added, respectively (Figure 20I). [Figure 20E-G] Same as above. [Figure 20H] Same as above. [Figure 20I] Same as above. [Figure 21A-B]Figures 21A–21J demonstrate that dual targeting, fragmentation signaling, and a single CD3ζ endodomain prevent tumor evasion due to antigen deficiency. Figure 21A shows flow cytometry histograms indicating GD2 and B7-H3 expression in NB cell lineage SH-SY5Y. Representative from three independent experiments. Figure 21B shows quantification of GD2 density on the cell membrane of CHLA-255, LAN-1, and SH-SY5Y cells as measured by flow cytometry. The numbers in the bars indicate the calculated number of GD2 molecules on the cell membrane of each cell lineage. Representative from two independent experiments. Figure 21C shows quantification of residual NB cells co-cultured with GFP-labeled CD19.28ζ, GD2.28ζ, and GD2.28ζ / B7-H3.BB CAR-T cells at a T cell to tumor cell ratio of 1:5. On day 5, NB cells (GFP+) and CAR-T cells (CD3+) were counted by flow cytometry. Data are shown as individual values and mean + SD. Independent co-culture with CAR-T cells generated from 10 different donors, n=10. One-way ANOVA with p-value correction by Tukey multiple comparison test yielded **p=0.0011, ****p<0.0001. Figures 21D-21E provide a summary of IFN-γ (Figure 21D) and IL-2 (Figure 21E) released by CAR-T cells in the culture supernatant after 24 hours of co-culture with NB, as measured by ELISA. Data are shown as individual values and mean + SD. Independent co-culture with CAR-T cells generated from 10 different donors, n=10. In Figure 21D, ***p=0.0001 for CD19.28ζ relative to GD2.28ζ / B7-H3.BB, and ***p=0.0002 for GD2.28ζ relative to GD2.28ζ / B7-H3.BB. In Figure 21E, ****p<0.0001. These were obtained by one-way ANOVA with p-value correction using Tukey multiple comparison tests. Figure 21F shows a scheme for an SH-SY5Y metastatic xenograft NB model in NSG mice treated with intravenous inoculation of 5 × 10⁵ FFLuc-SH-SY5Y cells via the tail vein, followed by intravenous injection of 1 × 10⁷ CD19.28ζ, GD2.28ζ, and GD2.28ζ / B7-H3.BB CAR-T cells 7 days later.Figures 21G–21H show representative tumor BLI images (Figure 21G) and BLI dynamics (Figure 21H) of FFLuc-SH-SY5Y tumor growth in metastatic xenograft NB models (mouse n=4 or 5 / group) shown in Figure 21F. Figure 21I shows Kaplan-Meier survival curves for mice (mouse n=4 or 5 / group) in Figures 21G–21H. Log-rank test shows p=0.0027. Figure 21J shows GD2 and B7-H3 expression levels in tumor cells collected from mice treated with CD19.28ζ or GD2.28ζ CAR-T cells analyzed by flow cytometry at the time of euthanasia. Representative of three independent experiments. [Figure 21C-E] Same as above. [Figure 21F-G] Same as above. [Figure 21H-J] Same as above. [Figure 22A-B]Figures 22A–22H demonstrate that GD2-specific CAR-T cells and B7-H3-specific CAR-T cells target neuroblastoma in vitro. Figure 22A provides flow cytometry histograms showing GD2 and B7-H3 expression in two human NB cell lines, CHLA-255 and LAN-1, representative from three independent experiments. Figure 22B provides representative flow cytometry histograms showing CAR expression in human T cells transduced with retroviral vectors encoding CD19.28ζ, GD2.28ζ, GD2.BBζ, B7-H3.28ζ, and B7-H3.BBζ CARs. Figures 22C–22E provide representative flow cytometry plots (Figure 22C) of residual CHLA-255 cells and LAN-1 cells co-cultured with CAR-T cells labeled with GFP at a 1:5 T cell-to-tumor cell ratio, as well as quantifications of residual CHLA-255 cells (Figure 22D) and LAN-1 cells (Figure 22E). On day 5, NB cells (GFP+) and CAR-T cells (CD3+) were counted by flow cytometry. Data are shown as individual values and mean + SD. Independent co-cultures n=6 using CAR-T cells generated from 6 donors. Figures 22F–22G provide a summary of IFN-γ (Figure 22F) and IL-2 (Figure 22G) released by CAR-T cells in the culture supernatant after 24 hours of co-culture with NB cells, as measured by ELISA. Data are shown as individual values and mean + SD. Independent co-cultures n=6 using CAR-T cells generated from 6 donors. Figure 22H shows representative CFSE dilutions (red histograms) of CSFE-labeled CAR-T cells co-cultured with NB cells for 5 days at a 1:1 T cell-to-tumor cell ratio. CFSE-labeled CAR-T cells alone (gray histogram) were used as a negative control. Representative from three independent experiments. [Figure 22D-F] Same as above. [Figure 22G-H] Same as above. [Figure 23A-B]Figures 23A–23H demonstrate the antitumor activity of GD2-specific CAR-T cells and B7-H3-specific CAR-T cells co-stimulated with either CD28 or 4-1BB in vivo. Figure 23A provides a scheme for a CHLA-255 metastatic xenograft NB model using NSG mice inoculated with 2 × 10⁶ FFluc-CHLA-255 cells by tail vein injection and then intravenously administered a high dose of CAR-T cells (6 × 10⁶ cells / mouse) 14 days later. Figures 23B–23C provide representative tumor bioluminescence (BLI) images (Figure 23B) and tumor BLI dynamics (Figure 23C) of FFluc-CHLA-255 tumor growth (n=3 mice for the CD19.28ζ group, n=5 mice for the other four groups) in the metastatic xenograft NB model shown in Figure 23A. Figure 23D shows the Kaplan-Meier survival curves for mice in Figures 23B-23C, with n=3 mice for the CD19.28ζ group and n=5 mice for the other four groups. Comparison of survival curves was determined by the log-rank test. **p=0.0042** for CD19.28ζ compared to the other four groups. Figure 23E shows a scheme for a LAN-1 metastatic xenograft NB model using NSG mice inoculated with FFLuc-LAN-1 cells by tail vein injection and treated 21 days later with intravenous injection of low-dose CD19.28ζ, GD2.28ζ, GD2.BBζ, B7-H3.28ζ, or B7-H3.BBζ CAR-T cells. Figures 23F-23G provide representative tumor BLI images (Figure 23F) and tumor BLI dynamics (Figure 23G) of FFLuc-LAN-1 tumor growth (mice n=3 / group). Figure 23H shows the Kaplan-Meier survival curves for mice, n=3 / group, in Figures 23F-23G. The comparison of survival curves was determined by the log-rank test. *p=0.0253 for CD19.28ζ compared to the GD2.28ζ, GD2.BBζ, and B7-H3.BBζ groups. *p=0.0295 for GD2.28ζ compared to GD2.BBζ. *p=0.0246 for GD2.28ζ compared to B7-H3.BBζ. [Figure 23C-D] Same as above. [Figure 23E-F] Same as above. [Figure 23G-H] Same as above. [Figure 24A-B]Figures 24A–24E demonstrate that the addition of tandem 4-1BB to the GD2.28ζ CAR and co-expression of both the GD2.28ζ CAR and the B7-H3.BBζ CAR do not improve antitumor activity in vitro. Figure 24A provides representative flow cytometry histograms showing CAR expression in human T cells transduced with retroviral vectors encoding CD19.28ζ, GD2.28ζ, GD2.28.BBζ, or GD2.28ζ / B7-H3.28ζ CARs. Representative from six independent experiments. Figures 24B–24C provide representative flow cytometry plots of GFP-labeled residual CHLA-255 cells co-cultured with CAR-T cells at a 1:5 T cell-to-tumor cell ratio (Figure 24B), and quantification of the said residual CHLA-255 cells (Figure 24C). Data are shown as individual values and mean + SD. Independent co-cultures using CAR-T cells generated from 6 or 8 different donors, n=6 or 8. Figures 24D–24E provide a summary of IFN-γ (Figure 24D) and IL-2 (Figure 24E) released by CAR-T cells in the culture supernatant after 24 hours of co-culture with NB cells, as measured by ELISA. Data are shown as individual values and mean + SD. Independent co-cultures using CAR-T cells generated from 6 or 8 different donors, n=6 or 8. One-way ANOVA with p-value correction in Tukey multiple comparison test showed **p=0.0011, ****p<0.0001. [Figure 24C-E] Same as above. [Figure 25A]Figures 25A–25G demonstrate that the cytotoxic activity of dual CAR-T cells with shared CD3ζ is antigen-dependent. Figure 25A provides flow cytometry plots showing B7-H3 and GD2 expression in wild-type Raji cells, as well as B7-H3 expression in Raji cells transduced with a retroviral vector encoding B7-H3 (Raji-B7-H3). Representative from three independent experiments. Figures 25B-25D show that CAR-T cells (B7-H3.BB, B7-H3.BBζ, GD2.28ζ, GD2.28ζ / B7-H3.BB, dNGFR.28ζ / B7-H3.BB, and 28ζ / B7-H3.BB) were co-cultured with Raji-B7-H3 cells in a 1:1 ratio. Tumor cells (CD19+) and T cells (CD3+) were collected after 5 days and counted by flow cytometry (Figure 25B). The supernatant of the co-culture was collected after 24 hours, and IFN-γ (Figure 25C) and IL-2 (Figure 25D) released by CAR-T cells were measured by ELISA. Data are shown as individual values and mean + SD. For the dNGFR.28ζ / B7-H3.BB group, independent co-cultures were performed using CAR-T cells generated from three different donors (n=3), and for all other groups, independent co-cultures were performed using CAR-T cells generated from five different donors (n=5). One-way ANOVA with p-value correction using Tukey multiple comparison tests showed *p<0.05 (0.0228 in Figure 25C, 0.0141 in Figure 25D), **p<0.01 (0.0025 in Figure 25C, 0.0015 in Figure 25D), ***p=0.0005, and ****p<0.0001. Figures 25E-25G show that CAR-T cells (CD19.28ζ, GD2.28ζ / B7-H3.BB, dNGFR.28ζ / B7-H3.BB, and 28ζ / B7-H3.BB) were co-cultured with wild-type Raji cells in a 1:1 ratio. Tumor cells (CD19+) and T cells (CD3+) were collected after 5 days and counted by flow cytometry (Figure 25E). The supernatant of the co-culture was collected after 24 hours, and IFN-γ (Figure 25F) and IL-2 (Figure 25G) released by CAR-T cells were measured by ELISA. Data are shown as individual values and mean + SD.Independent co-cultures (n=4) using CAR-T cells generated from four different donors in each group. One-way ANOVA with p-value correction using Tukey multiple comparison tests showed ****p<0.0001. [Figure 25B-D] Same as above. [Figure 25E-G] Same as above. [Figure 26-1] Figure 26 shows CAR clustering and aggregation in CAR-T cells after CAR association. Representative confocal microscopy images show CAR molecular clustering in GFP-tagged GD2.28ζ (green) and B7-H3.BB (red) expressing T cells, with or without CAR association, using either the anti-14g2a idiotype antibody (1A7) or the B7-H3.Fc protein. Blue staining indicates DAPI. Shown are representative cells in a single field of view (63x magnification). Data are representative of three independent validations. White indicates a scale bar corresponding to 20 μm. [Figure 26-2] Same as above. [Figure 27A-B]Figures 27A–27F demonstrate the phenotypic analysis of CAR-T cells in vitro and in vivo. Figures 27A–27B show the frequencies of CD45RA+CCR7+, CD45RA-CCR7+, CCR7-CD28+CD27+, CCR7-CD28+CD27-, CCR7-CD28-CD27+, and CCR7-CD28-CD27- in CD4+ (Figure 27A) and CD8+ (Figure 27B) T cells 13 days after retroviral vector transduction and expansion in vitro. Data are shown as individual values and mean + SD, from independent experiments n=4 using CAR-T cells generated from four different donors. *p=0.0299, two-sided p-value determined by unpaired t-test. Figures 27C–27F show the flow cytometry analysis of peripheral blood CAR-T cells collected on day 14 from tumor-bearing mice injected with CAR-T cells. Figures 27C–27D show the frequencies of CD45RA+CCR7+, CD45RA-CCR7+, CCR7-CD28+CD27+, CCR7-CD28+CD27-, CCR7-CD28-CD27+, and CCR7-CD28-CD27- in CD4+ (Figure 27C) and CD8+ (Figure 27D) T cells. Data are shown as individual values and mean + SD. Five mouse samples, n=5. *p<0.05, two-sided p-values determined by unpaired t-test. Figures 27E–27F show the mean fluorescence intensity (MFI) of PD-1 (Figure 27E) and TIM-3 (Figure 27F) in T cells. Data are presented as individual values and as mean + SD. 5 mouse samples, n=5. *p=0.0109, ***p=0.0008, two-tailed p-values determined by unpaired t-test. [Figure 27C-D] Same as above. [Figure 27E-F] Same as above. [Figure 28A-B]Figures 28A–28O demonstrate that reversing the orientation of B7-H3-specific and GD2-specific CARs does not alter the beneficial effects of divisional costimulation and dual-targeted CAR-T cells with shared CD3ζ in vitro. Figure 28A provides a schematic diagram of retroviral vectors encoding B7-H3.28ζ, GD2.BB, and B7-H3.28ζ / GD2.BB CARs. Figure 28B provides representative flow cytometry plots of five independent experiments showing CAR expression. Figure 28C provides a summary of CAR transduction efficiency. Data are shown as individual values and mean + SD. Independent experiments n=5 or 7 using CAR-T cells generated from 5 or 7 different donors. One-way ANOVA with p-value correction in Tukey multiple comparison test showed ***p=0.002, ****p<0.0001. Figures 28D–28F show CAR-T cells co-cultured with CHLA-255-GFP at a T cell-to-tumor cell ratio of 1:5. IFN-γ (Figure 28E) and IL-2 (Figure 28F) released by CAR-T cells were measured by ELISA. On day 5, the number of tumor cells (GFP+) and CAR-T cells (CD3+) was measured by flow cytometry (Figure 12D). Data are shown as individual values and mean + SD. Independent co-cultures n=3 using CAR-T cells generated from three different donors. One-way ANOVA with p-value correction using Tukey multiple comparison test yielded *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. A complete list of p-values is available from the source data. Figure 28G shows the scheme of the repeated multi-round co-culture experiment. Tumor cells were seeded in 24-well plates the day before T cell addition. On day 0, CAR-T cells were added in a T cell to tumor cell ratio of 1:5. On days 4, 7, and 10, all T cells were collected and transferred to new wells in which 5 × 10⁵ NB cells had been seeded the previous day. T cells, tumor cells, and cytokines were quantified in each cycle. Figures 28H–28O show the multi-round co-culture described in Figure 28G with NB cell lines CHLA-255 (Figures 28H–28K) and LAN-1 (Figures 28L–28O).Summary of residual CHLA-255 (Figure 28H) and LAN-1 (Figure 28L) cells and T cell counts (Figure 28I, Figure 28M) at the end of each round of co-culture. Summary of IFN-γ (Figure 28J, Figure 28N) and IL-2 (Figure 28K, Figure 28O) released by CAR-T cells in the culture supernatant after 24 hours of co-culture with CHLA-255 (Figure 28J-28K) and LAN-1 (Figure 28N-28O) cells. Data are presented as individual values and mean + SD. Independent co-cultures n=6 using CAR-T cells generated from 6 different donors. One-way ANOVA with p-value correction using Tukey multiple comparison test yielded *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. A complete list of p-values is available from the source data. [Figure 28C-G] Same as above. [Figure 28H-K] Same as above. [Figure 28L-O] Same as above. [Figure 29A-B]Figures 29A–29E demonstrate that dual targeting with fragmentation co-stimulation and shared CD3ζ results in superior antitumor activity and better T cell persistence when mice are treated with inverted B7-H3-specific CARs and GD2-specific CARs in an NB model. Figure 29A shows the scheme of a CHLA-255 metastatic xenograft NB model in NSG mice. Eight-week-old female NSG mice were inoculated with 2 × 10⁶ FFLuc-labeled CHLA-255 cells by tail vein injection, and 14 days later the mice were treated with 2 × 10⁶ CD19.28ζ, B7-H3.28ζ, or B7-H3.28ζ / GD2.BB CAR-T cells by tail vein injection. Figures 29B-29C show representative tumor bioluminescence (BLI) images (Figure 29B) and tumor BLI dynamics (Figure 29C) of FFLuc-CHLA-255 tumor growth in the metastatic xenograft NB model shown in Figure 29A (n=3 mice for the CD19.28ζ group, n=5 mice for the other two groups). Figure 29D shows the Kaplan-Meier survival curves for mice (n=3 mice for the CD19.28ζ group, n=5 mice for the other two groups) in Figures 29B-29C. Log-rank test shows **p=0.0016 (B7-H3.28ζ vs. B7-H3.28ζ / GD2.BB). Figure 29E shows flow cytometry detection of circulating CAR-T cells (CD45+CD3+) in mice 14 days after CAR-T cell treatment. Data are presented as individual values and mean + SD (n=3 samples from 3 mice for the CD19.28ζ group, and n=5 samples from 5 mice for the other two groups). One-way ANOVA with p-value correction using Tukey multiple comparison test showed *p=0.0144 and **p=0.0042. [Figure 29C-E] Same as above. [Figure 30A-C]Figures 30A–30H demonstrate that MSLN and CSPG4 dual-targeted CAR-T cells with fractional costimulation and shared CD3ζ exhibit sustained T cell activation and proliferation in vitro. Figure 30A provides a representative flow cytometry plot showing CAR expression. Figure 30B shows a summary of CAR transduction efficiency (independent experiments n=7 or 9 using CAR-T cells generated from 7 or 9 different donors). Data are shown as individual values and mean + SD. Figures 30C–30E show CAR-T cells co-cultured with GFP-labeled H2052 cells at a T cell to tumor cell ratio of 1:5. IFN-γ (Figure 30D) and IL-2 (Figure 30E) released by CAR-T cells. On day 5, tumor cells (GFP+) and CAR-T cells (CD3+) were measured by flow cytometry (Figure 30C). Data are shown as individual values and mean + SD. For the CSPG4.BBζ group, there were 3 independent co-cultures using CAR-T cells generated from 3 different donors; for the other groups, there were 5 independent co-cultures using CAR-T cells generated from 5 different donors. One-way ANOVA with p-value correction using Tukey multiple comparison tests yielded *p<0.05, **p<0.01, ***p<0.001, and ****p<0.0001. A complete list of p-values is available from the source data. Figure 30F shows the scheme of the multi-round co-culture experiment of CAR-T cells and H2052. Tumor cells were seeded the day before T cell addition. On day 0, CAR-T cells were added in a T cell to tumor cell ratio of 1:5. At the end of each co-culture round, on days 5, 9, 13, and 17, one-third of the T cells were collected and transferred to new wells seeded the previous day with 2.5 × 10⁵ H2052 cells. T cells and tumor cells, as well as cytokines released by CAR-T cells, were quantified in each round of co-culture. Figures 30G–30H show a summary of IFN-γ (Figure 30G) and IL-2 (Figure 30H) released by CAR-T cells in the multi-round co-culture described in Figure 30F with H2052. Data are shown as individual values and mean + SD.For the CSPG4.BBζ group, independent co-cultures were performed using CAR-T cells generated from three different donors (n=3); for the other groups, independent co-cultures were performed using CAR-T cells generated from four different donors (n=4). One-way ANOVA with p-value correction using Tukey multiple comparison tests yielded the following results: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. A complete list of p-values is available from the source data. [Figure 30D-F] Same as above. [Figure 30G-H] Same as above. [Figure 31A-B] Figures 31A-31D demonstrate that bispecific GD2 and B7-H3 CAR-T cells with fractional costimulation and shared CD3z exhibit superior antitumor activity and prevent antigen evasion in a high tumor-burdened xenograft model in which neuroblastoma cells exhibit heterogeneous GD2 expression. Figure 31A shows a scheme for a high tumor-burdened SH-SY5Y metastatic xenograft NB model using NSG mice inoculated with FFLuc-SH-SY5Y cells (1 × 10⁶ cells / mouse) by tail vein injection and treated 7 days later with intravenous injection of CD19.28ζ, GD2.28ζ, or GD2.28ζ / B7-H3BB CAR-T cells (1 × 10⁷ cells / mouse). Figures 31B–31C provide representative tumor bioluminescence (BLI) images (Figure 31B) and tumor BLI dynamics (Figure 31C) of FFLuc-SH-SY5Y tumor growth (mouse n=5 / group) in the metastatic xenograft NB model shown in Figure 31A. Figure 31D shows the Kaplan-Meier survival curves for mice and mice n=5 / group in Figures 31B–31C, and the comparison of survival curves was determined by the log-rank test. **p=0.0023** for CD19.28ζ compared to GD2.28ζ, and **p=0.0027** for GD2.28ζ / B7-H3.BB. [Figure 31C-D] Same as above. [Figure 32] Figure 32 shows the KEGG pathway analysis of the top 100 loaded PC2 genes in Figure 20E. Nominal p-values and FDR q-values were calculated using GSEA software (Broad Institute). [Modes for carrying out the invention]
[0018] Detailed description of the invention Preventing tumor evasion due to heterogeneous antigen expression and providing optimal T cell costimulation remain crucial aspects of obtaining clinical responses with CAR T cells in solid tumors. CAR-T cells that simultaneously target two antigens and provide optimal costimulation and T cell metabolic compatibility by independently activating the CD28 and 4-1BB pathways and modulating CD3ζ chain-mediated signaling are described herein. Modified T cells expressing dual CARs exhibit robust and sustained antitumor activity under in vivo stress conditions and prevent tumor evasion due to heterogeneous antigen expression by tumor cells.
[0019] modified T cells Aspects of this disclosure relate to modified T cells. In some embodiments, modified T cells are T cells engineered with a chimeric antigen receptor (CAR). CAR T cells are produced by obtaining T cells, e.g., T cells from a subject that needs them, or T cells from a donor subject, and by engineering those cells so that they contain a chimeric antigen receptor (CAR). CARs provide the ability to target specific proteins on cancer cells and typically include an antigen recognition domain, an extracellular hinge region, a transmembrane domain, and an intracellular T cell signaling domain. CAR T cells can be classified as first-generation, second-generation, third-generation, or fourth-generation. First-generation CARs are engineered using only the CD3ζ domain. Second-generation CARs are engineered using the CD3ζ domain and a co-stimulatory signaling domain (e.g., CD28 or 4-1BB). Third-generation CARs are engineered to contain the CD3ζ domain in addition to two co-stimulatory signaling domains (e.g., both CD28 and CD137). Finally, fourth-generation CARs, also known as T-cells redirected for universal cytokine-mediated killing (TRUCK), are engineered to include a CD3ζ domain, two co-stimulatory signaling domains (e.g., both CD28 and CD137), and some additional genetic modification, such as the addition of a transgene for cytokine secretion or an additional co-stimulatory signaling domain. Modified T cells containing CARs that result in bispecificity and bi-co-stimulation are described herein.
[0020] In some embodiments, the T cells are human T cells or non-human T cells. In some embodiments, mammalian cells are used. In some embodiments, the mammalian cells are primate cells (human or non-human primate cells), rodent (e.g., mouse, rat, rabbit, hamster) cells, canids, felines, bovines, or other mammalian cells. In some embodiments, avian cells are used. In some embodiments, the T cells are tumor-specific T cells.
[0021] In some embodiments, T cells are αβT cells, cytotoxic T lymphocytes (CTLs), regulatory T cells, natural killer T (NKT) cells, Th17 cells, γδT cells, or any combination thereof. In some embodiments, T cells are self-cells. In some embodiments, T cells are not self-cells. In some embodiments, T cells are T cells of the same species as the subject. In some embodiments, T cells are T cells of a different species than the subject.
[0022] In certain embodiments, the modified T cells are engineered to contain a dual-targeting CAR. In some embodiments, the dual-targeting CAR has a split-costimulatory signal and a single CAR-CD3ζ domain. In some embodiments, the modified T cells co-stimulate CD28 and 4-1BB. In some embodiments, the modified T cells express GD2 and B7-H3. In certain embodiments, the modified T cells contain GD2.28ζ.CAR / B7-H3.BB.CAR.
[0023] The modified T cells described herein exhibit one or more features. Non-limiting examples of modified T cell features include: biantigen specificity and co-stimulation; T cell toxic activity and cytokine release by GD2.28ζCAR or B7-H3.BB.CAR; increased release of IFN-γ and IL-2 (compared to control cells); higher basal levels of TCR activation signaling (compared to control cells); enhanced phosphorylation of CAR-CD3ζ chain and downstream signaling kinases (e.g., ERK and Akt); enrichment of cell cycle pathways (e.g., 5 days after antigen stimulation removal); enrichment of TCR signaling pathways (e.g., 5 days after antigen stimulation removal); increased glycolytic activity (compared to control cells on days 0 and 5 post-stimulation); control of tumor growth upon tumor re-administration (compared to control cells); promotion of enhanced tumor control and improved survival (compared to control cells); increased antitumor activity (e.g., under stress conditions); and combinations thereof. In some embodiments, modified T cells exhibit biantigen specificity and co-stimulation. In some embodiments, modified T cells exhibit T cell-killing activity and cytokine release via GD2.28ζ.CAR or B7-H3.BB.CAR. In some embodiments, modified T cells show increased IFN-γ and IL-2 release compared to control cells. In some embodiments, modified T cells exhibit higher basal levels of TCR activation signaling compared to control cells. In some embodiments, modified T cells show enhanced phosphorylation of the CAR-CD3ζ chain and downstream signaling kinases (e.g., ERK and Akt). In some embodiments, modified T cells show enrichment in cell cycle pathways (e.g., on day 5 after antigen stimulation). In some embodiments, modified T cells show enrichment in the TCR signaling pathway (e.g., on day 5 after antigen stimulation). In some embodiments, modified T cells show increased glycolytic activity compared to control cells (e.g., on days 0 and 5 after stimulation). In some embodiments, modified T cells control tumor growth upon tumor re-administration compared to control cells. In some embodiments, modified T cells promote enhanced tumor control and improved survival compared to control cells.In some embodiments, modified T cells exhibit increased antitumor activity (e.g., under stress conditions).
[0024] In some embodiments, T cells are isolated from mammals and genetically modified (i.e., transduced or transfected in vitro) with a split-costimulatory signal and a dual-targeting CAR having a single CAR-CD3ζ domain. In some embodiments, T cells can be transduced with a viral vector or transfected with a plasmid or nucleic acid construct. In some embodiments, the modified T cells are tumor-specific T cells transduced with the supernatant of a retroviral containing GD2.28ζ.CAR / B7-H3.BB.CAR.
[0025] For administration to a subject, modified T cells produced by the methods disclosed herein may be administered to the subject, for example, in the form of a pharmaceutically acceptable composition. These pharmaceutically acceptable compositions contain a therapeutically effective amount of the modified T cells formulated with one or more pharmaceutically acceptable carriers (additives) and / or diluents. In some embodiments, the pharmaceutical composition containing modified T cells further comprises diluents and / or other components and / or other cytokines and / or cell populations.
[0026] The pharmaceutical compositions of the present invention, as described herein, can be specifically formulated for administration in solid or liquid form and are suitable for: (1) oral administration, e.g., aqueous drugs (aqueous or non-aqueous solutions or aqueous or non-aqueous suspensions), lozenges, sugar-coated tablets, capsules, pills, tablets (e.g., those targeted for buccal, sublingual, and systemic absorption), boluses, powders, granules, and pastes for application to the tongue; (2) parenteral administration, e.g., by subcutaneous, intramuscular, intravenous, or epidural injection, e.g., as sterile solutions or suspensions or sustained-release formulations; (3) topical application, e.g., as creams, ointments, or controlled-release patches or sprays applied to the skin; (4) vaginal or rectal administration, e.g., as pessaries, creams, or foams; (5) sublingual; (6) ocular; (7) transdermal; (8) transmucosal; or (9) transnasal. In addition, the compounds can be implanted in the patient or injected using a drug delivery system. For example, see Urquhart, et al., Ann. Rev. Pharmacol. Toxicol. 24: 199-236 (1984); Lewis, ed. "Controlled Release of Pesticides and Pharmaceuticals" (Plenum Press, New York, 1981); U.S. Patent No. 3,773,919 and U.S. Patent No. 353,270,960. In some embodiments, direct administration to the tumor, and / or to the body cavity, opening and / or tissue containing the tumor may be desirable.
[0027] As used herein, the term “pharmaceutically acceptable” means a compound, material, composition and / or dosage form that, within reasonable medical judgment, is suitable for use in contact with human and animal tissues, without excessive toxicity, irritation, allergic reactions or other problems or complications, and is commensurate with a reasonable risk-reward ratio.
[0028] As used herein, the term “pharmaceutically acceptable carrier” means a pharmaceutically acceptable material, composition, or vehicle involved in transporting or carrying the compound of interest from one organ or part of the body to another organ or part of the body, such as a liquid or solid filler, diluent, excipient, manufacturing aid (e.g., lubricant, talc, magnesium stearate, calcium or zinc, or stearic acid), or solvent encapsulation material. Each carrier must be “acceptable” in the sense that it is compatible with the other components of the formulation and is not harmful to the patient. Some examples of materials that can serve as pharmaceutically acceptable carriers include: (1) sugars, e.g., lactose, glucose, and sucrose; (2) starches, e.g., corn starch and potato starch; (3) cellulose and its derivatives, e.g., sodium carboxymethylcellulose, methylcellulose, ethylcellulose, microcrystalline cellulose, and cellulose acetate; (4) tragacanth powder; (5) malt; (6) gelatin; (7) lubricants, e.g., magnesium stearate, sodium lauryl sulfate, and talc; (8) excipients, e.g., cocoa butter and suppository wax; (9) oils, e.g., peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; (10 (1) Glycols, e.g., propylene glycol; (11) Polyols, e.g., glycerin, sorbitol, mannitol, and polyethylene glycol (PEG); (12) Esters, e.g., ethyl oleate and ethyl laurate; (13) Agar; (14) Buffers, e.g., magnesium hydroxide and aluminum hydroxide; (15) Alginic acid; (16) Pyrogen-free water; (17) Isotonic saline; (18) Ringer's solution; (19) Ethyl alcohol; (20) pH buffer solution; (21) Polyesters, polycarbonates, and / or polyanhydrides; (22) Bulking agents, e.g., polypeptides and amino acids; (23) Serum components, e.g., serum albumin, HDL, and LDL; (22) C2-C 12Examples include alcohols, such as ethanol; and (23) other non-toxic, compatible substances used in pharmaceutical formulations. Wetting agents, colorants, release agents, coating agents, sweeteners, flavoring agents, fragrances, preservatives, and antioxidants may also be present in the formulations. These terms, such as “excipient,” “carrier,” and “pharmaceutically acceptable carrier,” are used synonymously herein.
[0029] Treatment method Methods for treating or preventing cancer in subjects requiring such treatment are disclosed herein. In some embodiments, the method includes the step of administering modified T cells comprising a splitting costimulatory signal and a bitargeted CAR having a single CAR-CD3ζ domain as described herein. In some embodiments, the method includes the step of administering a therapeutically effective dose of modified T cells comprising a splitting costimulatory signal and a bitargeted CAR having a single CAR-CD3ζ domain.
[0030] Methods for generating populations of modified T cells in subjects (e.g., subjects diagnosed with cancer, and / or subjects otherwise requiring it) are also disclosed herein. In some embodiments, the method includes administering T cells modified to include a splitting costimulatory signal and a dual-targeting CAR having a single CAR-CD3ζ domain to a subject. In some embodiments, the population of modified T cells persists in the subject for a period of time after administration (e.g., at least 1 week, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 9 months, 1 year, 2 years, 5 years, etc.). In some embodiments, the population of modified T cells persists in the subject for a period of 3 to 9 months after administration, and in certain embodiments for a period of 6 months.
[0031] In some embodiments, the cells described herein, for example, modified T cells, are transplantable, and for example, modified T cells can be administered to a subject. In some embodiments, the subject to which the modified T cells are administered is the same subject from which the original T cells were obtained (for example, for autologous cell therapy). In some embodiments, the subject is a different subject. In some embodiments, the subject is cancerous or a normal subject. For example, modified T cells for transplantation may be in a form suitable for transplantation.
[0032] The method may further include the step of administering modified T cells to a subject in need, for example, a mammalian subject, for example, a human subject. The cell source may be a mammal, preferably a human. The cell source or recipient may also be a non-human subject, for example, an animal model. The term “mammal” includes organisms including mice, rats, cows, sheep, pigs, rabbits, goats, horses, monkeys, dogs, cats, and preferably humans. Similarly, transplantable cells may be obtained from any of these organisms, including non-human transgenic organisms.
[0033] Compositions containing modified T cells can be administered to a target using an implantable device. Implantable devices and related technologies are known in the art and are useful as delivery systems when continuous or sustained-release delivery of the compounds or compositions described in detail herein is desired. In addition, implantable device delivery systems are useful for targeting specific delivery sites (e.g., localization sites, organs) of compounds or compositions. Negrin et al., Biomaterials, 22(6):563 (2001). Sustained-release technologies relating to other delivery methods can also be used in the present invention. For example, dissociable formulations based on polymer technologies, sustained-release techniques and encapsulation techniques (e.g., polymer encapsulation techniques, liposome encapsulation techniques) can also be used for the delivery of the compounds and compositions described in detail herein.
[0034] As used herein, the term “administer” refers to the placement of a composition onto a subject by a method or route that results in the composition being at least partially localized to a desired location in order to produce the desired effect. Preferred administration routes for the methods of the present invention include both topical and systemic administration. Generally, topical administration results in more of the administered modified T cells being delivered to a specific location compared to the whole body of the subject, while systemic administration results in the modified T cells being delivered essentially throughout the whole body of the subject.
[0035] In the context of administering modified T cells, the term “administering” also includes the transplantation of such cells in a subject. As used herein, the term “transplantation” refers to the process of implanting or transplanting at least one cell into a subject. The term “transplantation” includes, for example, autologous transplantation (removing cells from one location in a patient and moving them to the same or another location in the same patient), allogeneic transplantation (transplantation between members of the same species), and xenotransplantation (transplantation between members of different species). Those skilled in the art will be well aware of methods for implanting or transplanting cells to treat cancer that are suitable for the present invention.
[0036] Modified T cells or compositions containing them can be administered by any suitable route known in the art, including but not limited to oral or parenteral routes, including intravenous, intramuscular, subcutaneous, transdermal, respiratory (aerosol), pulmonary, nasal, rectal, and topical (including buccal and sublingual) administration.
[0037] Exemplary modes of administration include, but are not limited to, injection, infusion, drip infusion, inhalation, or ingestion. "Injection" includes, but is not limited to, intravenous, intramuscular, intra-arterial, intrathecal, intraventricular, intra-articular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subepidermal, intra-articular, subcapsular, subarachnoid, intraspinal, intracerebrospinal, and intrasternal injections and infusions. In preferred embodiments, the composition is administered by intravenous infusion or injection.
[0038] As used herein, “subject” means human or animal. Typically, animals are vertebrates, e.g., primates, rodents, domestic animals, or game animals. Primates include chimpanzees, cynomologous monkeys, spider monkeys, and macaques, e.g., rhesus monkeys. Rodents include mice, rats, marmosets, ferrets, rabbits, and hamsters. Domestic and game animals include cows, horses, pigs, deer, bison, buffalo, felines, e.g., domestic cats, canids, e.g., dogs, foxes, wolves, birds, e.g., chickens, emus, ostriches, and fish, e.g., trout, catfish, and salmon. Patient or subject includes any subset of those described above, e.g., all of those described above except one or more groups or species such as humans, primates, or rodents. In certain embodiments of the aspects described herein, the subject is a mammal, for example, a primate, for example, a human. The terms “patient” and “subject” are used synonymously herein. The subject may be male or female.
[0039] Preferably, the subject is a mammal. Mammals may be, but are not limited to, humans, non-human primates, mice, rats, dogs, cats, horses, or cows. In addition, the methods and compositions described herein may be used to treat domesticated animals and / or pets.
[0040] In some embodiments, a subject is considered to have cancer, develop cancer, or be at risk of cancer recurrence. Whether a subject has cancer, develops cancer, or is at risk of cancer recurrence is a decision that may be within the scope of the judgment of the skilled caregiver of the subject. Any suitable diagnostic tests and / or criteria may be used. For example, a subject may be considered to have cancer or be at risk of developing cancer if (i) the subject has mutations, genetic polymorphisms, gene or protein expression profiles, and / or the presence of certain substances in the blood that are associated with an increased risk of developing or having cancer compared to other members of the general population who do not have mutations or genetic polymorphisms; (ii) the subject has one or more risk factors, such as a family history of cancer, carcinogenic or tumor-promoting substances or conditions, e.g., asbestos, tobacco smoke, aflatoxins, radiation, chronic infection / inflammation, or advanced age; (iii) the subject has one or more symptoms of cancer; or (iv) the subject has a medical condition that is known to increase the likelihood of cancer.
[0041] As used herein, the type of cancer is not limited. The term “cancer” as used herein is defined as the overgrowth of cells whose unique characteristic—loss of normal control—results in uncontrolled growth, lack of differentiation, local tissue invasion, and metastasis. For the purposes of this invention, cancer includes acute lymphoblastic cancer, acute myeloid leukemia, adenocarcinoma, alveolar rhabdomyosarcoma, anal cancer, angiosarcoma, B-cell lymphoma, basal cell carcinoma, bladder cancer, bone cancer, brain cancer, breast cancer, cancer of the anus, anal canal or anorectum, eye cancer, intrahepatic cholangiocarcinoma, joint cancer, cancer of the neck, bladder or pleura, cancer of the nose, nasal cavity or middle ear, oral cancer, vulvar cancer, chronic lymphocytic leukemia, chronic myeloid cancer, colon cancer, colorectal cancer, esophageal cancer, cervical cancer, endometrial cancer, fibrosarcoma, gastrointestinal carcinoid tumor, hematopoietic neoplasm, and Hodgkin's cancer. It may be any cancer, including any of the following: patoma, hypopharyngeal cancer, kidney cancer, pharyngeal cancer, leukemia, humoral neoplasm, liver cancer, lung cancer, lymphoma, malignant mesothelioma, mast cell tumor, melanoma, multiple myeloma, myeloma, nasopharyngeal cancer, non-Hodgkin lymphoma, ovarian cancer, pancreatic cancer, peritoneal, reticular, and mesenteric cancer, pharyngeal cancer, prostate cancer, rectal cancer, kidney cancer, sarcoma, skin cancer, small intestine cancer, soft tissue cancer, solid tumor, squamous cell carcinoma, gastric cancer, T-cell lymphoma, testicular cancer, thymoma, thyroid cancer, ureteral cancer, bladder cancer, and uterine cancer. In certain embodiments, cancer is neuroblastoma. As used herein, the term “tumor” means malignant growth of cells or tissues and does not include benign tissues unless otherwise specifically indicated.
[0042] As used herein, the terms “to treat” and “treatment” mean administering to a subject an effective amount of modified T cells, ex vivo modified according to the methods described herein, such that the subject has relief of at least one symptom of the disease or improvement of the disease, e.g., a beneficial or desired clinical outcome. For the purposes of the present invention, a beneficial or desired clinical outcome includes, but is not limited to, relief of one or more symptoms, reduction of the severity of the disease, stabilization of the disease (i.e., no worsening), delay or slowing of disease progression, improvement or reduction of the disease, and remission (whether partial or complete remission), whether detectable or undetectable. To treat may also mean extending survival compared to the expected survival without treatment. Thus, it will be understood by those skilled in the art that treatment may not result in a complete cure of the disease but may improve the disease state. As used herein, the terms “treatment” include prevention. Alternatively, treatment is “effective” if the progression of the disease is reduced or halted. “Treatment” may also mean extending survival compared to the expected survival without treatment. Those requiring treatment include not only those already diagnosed with a disorder related to the expression of polynucleotide sequences, but also those who are highly likely to develop such a disorder due to genetic susceptibility or other factors.
[0043] "Treatment," "prevention," or "improvement" of a disease or disorder means delaying or preventing the onset of such disease or disorder, or reversing, mitigating, improving, inhibiting, slowing, or stopping the progression, exacerbation, or worsening of the progression or severity of a condition associated with such disease or disorder. In one embodiment, the symptoms of the disease or disorder are mitigated by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, or at least 50%.
[0044] The dosage, administration schedule, and method of administration of modified T cells are not limited. The dosage will depend on various factors, including other treatments, the number of doses, and individual patient parameters, including age, health status, size, and weight. These are factors well known to those skilled in the art and can be addressed simply through routine experimentation. In some embodiments, the maximum tolerable dose, i.e., the highest dose that is safe and acceptable according to reasonable medical judgment, may be used. In some embodiments, the pharmaceutical composition containing modified T cells is administered in approximately 10 doses. 3 ~about 10 10 It can be administered in doses of cells / kg body weight, and in some embodiments, the dose is about 10 5 ~about 10 6 This can be expressed as cells / kg body weight, and this dosage can include all integer values within this range (e.g., 10 4 , 10 5 , 10 6 , 10 7 , 10 8 , 10 9 ) is included.
[0045] The dose used may be the maximum tolerated dose, a dose below the therapeutic dose, or any dose in between. In some embodiments, modified T cells are administered in combination with one or more agents. In some embodiments, modified T cells and / or one or more agents are administered according to a defined dosing schedule. Multiple doses are intended. In some embodiments, when modified T cells and one or more agents are administered in combination, doses below the therapeutic dose of one or more agents may be used. "Dose below the therapeutic dose," as used herein, means a dose that is less than the dose that would produce a therapeutic outcome in a subject when administered in the absence of other agents. In some embodiments, a dose below the therapeutic dose of an anticancer agent is a dose that would not produce a useful therapeutic outcome in a subject in the absence of the administration of modified T cells described herein. Therapeutic doses of anticancer agents are well known in the pharmaceutical field for the treatment of cancer.
[0046] As used herein, a pharmaceutical composition comprises one or more therapeutically useful agents or compositions, and a pharmaceutically acceptable carrier, e.g., a carrier that facilitates the delivery of the agent or composition. The agents and pharmaceutical compositions disclosed herein may be administered by any preferred means, e.g., orally, intranasally, subcutaneously, intramuscularly, intravenously, intra-arterially, parenterally, intraperitoneally, intrathecally, intratracheally, orally, sublingually, vaginally, rectally, cutaneously, or as an aerosol. Depending on the type of condition to be treated (e.g., cancer), the compounds of the present invention may be administered, for example, by inhalation, ingestion, or by systemic routes. Thus, various modes or routes of administration are available. The particular mode of selection will generally depend on factors such as the particular compound selected, the particular condition to be treated, and the dosage required for therapeutic efficacy. Generally speaking, the methods described herein may be carried out using any medically acceptable mode of administration, meaning any mode that produces an acceptable level of efficacy without causing clinically unacceptable adverse effects. Preferred modes of administration are parenteral and oral routes. The term "parenteral" includes subcutaneous, intravenous, intramuscular, intraperitoneal, and intrasternal injection or infusion techniques. In some embodiments, inhalation therapy is particularly useful, for example, in lung cancer patients, because it delivers directly to the lungs. Several types of metered-dose inhalers are routinely used for administration by inhalation. These types of devices include metered-dose inhalers (MDIs), respiratory-actuated MDIs, dry powder inhalers (DPIs), spacer / holding chambers in combination with MDIs, and nebulizers. In some embodiments, the drug is delivered by aerosol for lung disease. Other suitable routes will be apparent to those skilled in the art.
[0047] The toxicity and therapeutic efficacy of a composition containing modified T cells can be determined, for example, by standard pharmaceutical procedures in cell cultures or experimental animals to determine the LD50 (lethal dose for 50% of the population) and ED50 (effective dose for 50% of the population). Compositions containing modified T cells that exhibit a large therapeutic index are preferred.
[0048] The amount of a composition containing modified T cells can be tested using several well-established animal models.
[0049] In some embodiments, data obtained from cell culture assays and animal studies can be used to formulate dosage ranges for human use. Doses of such compounds are preferably within the range of circulating concentrations containing little to no toxicity in the ED50. Doses may vary within this range depending on the dosage form used and the route of administration utilized.
[0050] The therapeutically effective dose of a composition containing modified T cells can first be estimated from a cell culture assay. Alternatively, the effect of any specific dosage can be monitored by a suitable bioassay.
[0051] It is commonplace for an experienced clinician to monitor the patient to determine when the therapeutic benefit of the treatment will be obtained, and to decide whether to increase or decrease the dosage, increase or decrease the frequency of administration, discontinue or restart the treatment, or make other changes to the treatment regimen, regarding the duration and frequency of the treatment. The medication schedule can vary from once a week to daily, depending on several clinical factors. The desired dose can be administered in one dose or divided into divided doses, e.g., 2 to 4 divided doses, and can be administered over a period of time, e.g., at appropriate intervals throughout the day or on another appropriate schedule. Such divided doses can be administered as unit dosage forms. In some embodiments, administration is once or multiple doses per day over a chronic period, e.g., several weeks or several months. Examples of medication schedules include daily, twice-daily, three-times-daily, or four-times-daily, or more frequently, over periods of one week, two weeks, three weeks, four weeks, one month, two months, three months, four months, five months, or six months or longer.
[0052] In another aspect of the present invention, the method provides the use of an isolated population of modified T cells. In one embodiment of the present invention, the isolated population of modified T cells disclosed herein can be used to produce a pharmaceutical composition for use in transplantation into subjects requiring treatment, such as subjects with cancer or subjects at risk of developing cancer. Examples include subjects with melanoma or pancreatic cancer. In some embodiments, the isolated population of modified T cells disclosed herein may be autologous and / or allogeneic. In some embodiments, the subjects are mammals, and in other embodiments, the mammals are humans.
[0053] One embodiment of the present invention relates to a method for treating cancer in a subject, comprising the step of administering an effective amount of a composition comprising modified T cells disclosed herein to a subject having cancer. Another embodiment relates to a method for treating neuroblastoma in a subject, comprising the step of administering an effective amount of a composition comprising modified T cells disclosed herein to a subject having neuroblastoma.
[0054] In some embodiments, the modified T cells disclosed herein are administered to subjects with cancer in combination with a second therapeutic treatment (e.g., chemotherapy, radiation, immunosuppressants such as cyclosporine, azathioprine, methotrexate, mycophenolate and FK506, antibodies, other immunoablation agents such as CAM PATH, anti-CD3 antibodies or other antibody therapies, cytotoxicities such as fludarabine, cyclosporine, FK506, rapamycin, mycophenolate, steroids, FR901228, cytokines, and / or irradiation).
[0055] In some embodiments, modified T cells are administered to a patient in conjunction with (e.g., before, concurrently with, and / or after) bone marrow transplantation, T cell ablation therapy using any of the chemotherapeutic agents such as fludarabine, external beam radiation therapy (XRT), cyclophosphamide, or antibodies such as OKT3 or CAMPATH. In other embodiments, modified T cells are administered after B cell ablation therapy using a CD20-reactive agent such as rituxan. For example, in one embodiment, a subject may undergo standard treatment with high-dose chemotherapy, followed by peripheral blood stem cell transplantation. In certain embodiments, after transplantation, the subject may receive an infusion of enlarged modified T cells. In additional embodiments, enlarged cells may be administered before and / or after surgery.
[0056] In the treatment of cancer or tumors, modified T cells may, if necessary, be administered in conjunction with other different cytotoxic agents, such as chemotherapy or antineoplastic compounds, or radiotherapy, which are useful for treating the disorders or conditions described herein (e.g., chemotherapy or antineoplastic compounds). Other compounds may be administered before, concurrently with, and / or after the administration of modified T cells. As used herein, the term “concurrently” means close enough in time to produce a combined effect (i.e., concurrently can mean simultaneously, or two or more administrations performed before or after each other).
[0057] As used herein, the phrase “radiotherapy” includes, but is not limited to, X-rays or gamma rays delivered from an externally applied source such as a beam, or by the implantation of a miniature radiation source.
[0058] Some non-limiting examples of suitable chemotherapeutic agents that may be administered with the modified T cells described herein include daunomycin, cisplatin, verapamil, cytosine arabinoside, aminopterin, demecolcine, tamoxifen, actinomycin D, alkylating agents (including, but not limited to, nitrogen mustard, ethyleneimine derivatives, alkyl sulfonates, nitrosourea, and triazenes): uracil mustard, chlormetine, cyclophosphamide (Cytoxan®), ifosfamide, melphalan, chlorambucil, pipobromane, triethylene-melamine, triethylenethiophosphoramine, busulfan, carmustine, lomustine, streptozosin, dacarbazine, and temozolomide; antimetabolites (including, but not limited to, folate antagonists, pyrimidine analogues); and folic acid antagonists. , including purine analogs and adenosine deaminase inhibitors): methotrexate, 5-fluorouracil, phloxuridine, cytarabine, 6-mercaptopurine, 6-thioguanine, fludarabine phosphate, pentostatin, and gemcitabine; natural products and their derivatives (e.g., vinca alkaloids, antitumor antibodies, enzymes, lymphokines, and epipodophyllotoxins): vinblastine, vincristine, vindesine, bleomycin, dactinomycin, daunorubicin, doxorubicin, epirubicin, idarubicin, Ara-C, paclitaxel (patlitaxel is marketed as Taxol®), mitramycin, deoxycoformycin, mitomycin-C, L-asparaginase, interferon (in particular IFN-a), etoposide, and teniposide. Other antiproliferative cytotoxic agents include navelben, CPT-11, anastrazole, letrazole, capecitabine, reloxafine, cyclophosphamide, ifosfamide, and droloxafine.Additional antiproliferative cytotoxic agents include, but are not limited to, melphalan, hexamethylmelamine, thiotepa, cytarabine, edatrexate, trimethrexate, dacarbazine, L-asparaginase, camptothecin, topotecan, bicalutamide, flutamide, leuprolide, pyridobenzoindole derivatives, interferon, and interleukin. Preferred classes of antiproliferative cytotoxic agents are EGFR inhibitors, Her-2 inhibitors, CDK inhibitors, and Herceptin® (tratuzumab). (See U.S. Patents No. 6,537,988 and 6,420,377). Such compounds can be administered according to techniques currently known for their administration.
[0059] In some embodiments, the modified T cells disclosed herein can be administered with any physiologically acceptable excipient to a site where the modified T cells can find a suitable site for replication, proliferation, and / or engraftment. In some embodiments, the modified T cells disclosed herein can be introduced by injection, catheter, etc. In some embodiments, the modified T cells disclosed herein can be frozen at liquid nitrogen temperature and stored for a long period of time, and then used upon thawing. When frozen, the modified T cells would typically be stored in 10% DMSO, 50% FCS, 40% RPMI 1640 medium. Upon thawing, the cells can be expanded by the use of growth factors and / or feeder cells associated with T cell culture.
[0060] In some embodiments, the modified T cells disclosed herein may be supplied in the form of a pharmaceutical composition containing an isotonic excipient prepared under sufficiently sterile conditions for administration to humans. For general principles regarding medical formulations, readers should refer to *Cell Therapy: Stem Cell Transplantation, Gene Therapy, and Cellular Immunotherapy*, by G. Morstyn & W. Sheridan eds, Cambridge University Press, 1996; and *Hematopoietic Stem Cell Therapy*, ED Ball, J. Lister & P. Law, Churchill Livingstone, 2000. The selection of cell excipients and any accompanying elements in the composition containing the modified T cells disclosed herein will vary depending on the route and device used for administration. In some embodiments, the composition containing the modified T cells may also contain or be accompanied by one or more other components that promote the engraftment or functional recruitment of the modified T cells. Preferred components include template proteins that support or promote the adhesion of modified T cells or complementary cell types. In another embodiment, the composition may include a reabsorbable or biodegradable mold scaffold.
[0061] In some embodiments, modified T cells may be administered and prescribed in accordance with a high standard of medical care, taking into account the individual patient's clinical condition, administration site and method, administration scheduling, patient's age, sex, weight, and other factors known to the physician. Therefore, the pharmaceutically effective dose for the purposes of this specification is determined by considerations known to the art. This dose must be effective in achieving improvements including, but not limited to, improved survival rates or more rapid recovery, or improvement or disappearance of symptoms and other indicators as appropriate evaluation criteria selected by those skilled in the art. Modified T cells may be administered to subjects in the following locations: clinics, offices, emergency departments, wards, intensive care units, operating rooms, catheterization labs, and radiology rooms.
[0062] In other embodiments, modified T cells are stored for later implantation / injection. Modified T cells can be divided into one or more fractions or units to apply some to a target immediately while retaining some for later application. Long-term storage of all or some cells from a cell bank, as disclosed in U.S. Patent Application Publication 2003 / 0054331 and Patent Publication WO03 / 024215, is also within the scope of the present invention and is incorporated herein by reference in whole. At the end of processing, enriched cells can be filled into a delivery device such as a syringe for placement to a recipient by any means known to those skilled in the art.
[0063] Pharmaceutical compositions containing an effective amount of modified T cells are also intended by the present invention. These compositions contain an effective number of modified T cells, as needed, in combination with pharmaceutically acceptable carriers, additives, or excipients. In certain indications, systemic administration of modified T cells to the subject may be preferred, while in other indications, direct administration to the tumor site or vicinity of the tumor may be preferred.
[0064] In some embodiments, the modified T cells may be packaged in a suitable container along with instructions for use that describe any desired purpose, such as reconstitution or thawing (if frozen) of the modified T cells before administration to a subject, as needed.
[0065] Specific examples of certain aspects of the present invention disclosed herein are shown in the following examples.
[0066] It will be readily apparent to those skilled in the art that the present invention is well suited to achieving its objectives and obtaining the results and benefits described herein, as well as the consequences associated therewith. The details of the descriptions and examples herein are representative of certain embodiments, illustrative, and not intended to limit the scope of this disclosure. Modified forms and other uses will come to mind to those skilled in the art. These modified forms are included within the spirit of the invention. It will be readily apparent to those skilled in the art that various substitutions and modifications can be made to the invention disclosed herein without departing from the scope and spirit of the invention.
[0067] The articles “a” and “an,” as used herein and in these claims, should be interpreted to include multiple referents unless expressly indicated otherwise. Any claim or description containing “or” between one or more members of a group is considered valid if one, more than one, or all of the group members are present, used, or otherwise related to a given product or process, unless otherwise indicated or otherwise evident from the context. The present invention includes embodiments in which only one member of a group is present, used, or otherwise related to a given product or process. The present invention also includes embodiments in which more than one or all of the group members are present, used, or otherwise related to a given product or process. Furthermore, it should be understood that the present invention provides any variation, combination and permutation in which one or more limitations, elements, clauses, descriptive terms, etc., from one or more of the claims described herein are introduced into another claim dependent on the same basic claim (or, where appropriate, any other claim), unless otherwise indicated or unless it would be obvious to a person skilled in the art that such a change would result in a contradiction or inconsistency. All embodiments described herein are intended to be applicable to all different aspects of the present invention where appropriate. Any embodiment or aspect is also intended to be freely combined with one or more other such embodiments or aspects at any time where appropriate. Where elements are presented as a list, for example, in a Markush group or similar form, it should be understood that each subgroup of the elements is also disclosed, and any element may be removed from that group. In general, where the present invention or an aspect of the present invention is stated to include certain elements, features, etc., it should be understood that certain embodiments of the present invention or an aspect of the present invention consist of, or are essentially derived from, such elements, features, etc. For brevity, these embodiments are not necessarily explicitly shown herein in all cases, strictly speaking.It should also be understood that any embodiment or aspect of the present invention may be expressly excluded from the claims, whether or not specific exclusions are stated herein. For example, any one or more active agents, additives, components, agents as needed, types of organisms, ailments, subjects, or combinations thereof may be excluded.
[0068] Where a claim or description relates to a composition, it should be understood that a method of preparing or using a composition according to any of the methods disclosed herein, and a method of using a composition for any of the purposes disclosed herein, constitutes an embodiment of the present invention unless otherwise indicated, or unless it is obvious to a person skilled in the art that this would result in a contradiction or inconsistency. Where a claim or description relates to a method, it should be understood that, for example, a method of preparing a composition useful for carrying out the method, and a product produced according to the method, constitutes an embodiment of the present invention unless otherwise indicated, or unless it is obvious to a person skilled in the art that this would result in a contradiction or inconsistency.
[0069] Where a range is given herein, the present invention includes embodiments that include an endpoint, embodiments that exclude both endpoints, and embodiments that include one endpoint and exclude the other. Unless otherwise indicated, assume that both endpoints are included. Furthermore, unless otherwise indicated, or unless other interpretation is evident from the context and the understanding of those skilled in the art, the values expressed as a range can take any specific value or subrange within the range described with respect to the various embodiments of the present invention, up to one-tenth of the lower limit of that range, unless otherwise explicitly stated in the context. Where a set of numerical values is described herein, it is also understood that the present invention includes embodiments relating to any intervening value or range defined by any two of the values in that set of numerical values, and embodiments in which the lowest value can be considered the minimum value and the highest value can be considered the maximum value. Numerical values, where used herein, include values expressed as percentages. In any embodiment of the present invention in which a numerical value is preceded by "about" or "approximately," the present invention includes embodiments in which that very value is described. In any embodiment of the present invention in which the numerical value is not preceded by "approximately" or "about," the present invention also includes embodiments in which the value is preceded by "approximately" or "about."
[0070] As used herein, A and B are different terms used in the claims, and “A and / or B” generally means at least one of A, B, or both A and B. For example, one sequence that is complementary to and / or hybridizes to another sequence includes (i) one sequence that is complementary to the other sequence, even if that one sequence could not necessarily hybridize to the other sequence under all conditions; (ii) one sequence that hybridizes to the other sequence, even if that one sequence was not perfectly complementary to the other sequence; and (iii) a sequence that is both complementary to and hybridizes to the other sequence.
[0071] "Approximately" or "about" generally means a number that falls within 1% in either direction (greater than or less than the number) or, in some embodiments, within 5% of a number or, in some embodiments, within 10% of a number (unless such a number exceeds 100% of the possible value to an unacceptable degree). Unless expressly indicated otherwise, in any method claimed herein that includes more than one act, the order of the acts of the method is not necessarily limited to the order in which the acts of the method are described, but it should be understood that the present invention includes embodiments in which the order is thus limited. Unless expressly indicated otherwise, or unless other interpretation is evident from the context, it should also be understood that any product or composition described herein may be considered "isolated".
[0072] As used herein, the terms “contains” or “includes” are used in reference to compositions, methods, and their respective components that are essential to the present invention, but there is room to include elements not explicitly stated, whether essential or not.
[0073] As used herein, the term “essentially from” refers to the elements required for a given embodiment. The term allows for the presence of additional elements that do not significantly affect the basic, novel, or functional features of the embodiments of the present invention.
[0074] The term "consisting of" refers to the compositions, methods, and their respective components described herein, excluding any elements not mentioned in the description of the embodiments. [Examples]
[0075] (Example 1) result Single or dual CD28 or 4-1BB co-stimulated single or dual antigen-targeted CAR-T cells do not eradicate tumors under stress conditions. We used neuroblastoma (NB) as a tumor model and two tumor cell lines (CHLA-255 and LAN-1) that co-expressed two targetable antigens, GD2 and B7-H3, as assessed by flow cytometry (Figure 5A). T cells engineered to express GD2.28ζ.CAR, GD2.BBζ.CAR, B7-H3.28ζ.CAR, and B7-H3.BBζ.CAR effectively eliminated tumor cells in vitro without any significant difference (Figures 5C-5E). The cytolytic activity of CAR-T cells was confirmed by the release of IFN-γ and IL-2 into the culture supernatant (Figures 5F-5G) and by the proliferation of T cells in response to the NB cell line (Figure 5H). GD2.28ζ.CAR, GD2.BBζ.CAR, B7-H3.28ζ.CAR, and B7-H3.BBζ.CAR-T cells similarly and effectively controlled tumor growth in CHLA-255-engrafted NSG mice when high doses of CAR-T cells were used (Figures 6A-6D). In stark contrast, under stress conditions, e.g., CHLA-255-carrying mice with low doses of CAR-T cells (2 × 10⁶ 6 When CAR-T cells were used under stress conditions (Figure 1A) treated with CAR-T cells (of the same type as mice), GD2.28ζ.CAR-T cells showed superior tumor control compared to GD2.BBζ.CAR, B7-H3.28ζ.CAR, and B7-H3.BBζ.CAR-T cells (Figures 1B-1D). Similar results were observed in a second NB model in which LAN-1 cells were engrafted in mice (Figures 7A-7D).
[0076] GD2.28ζ.CAR-T cells did not completely eradicate the tumor at low doses, but showed the most significant antitumor activity, so the addition of 4-1BB costimulation was evaluated, as previously described. 11We determined whether this would lead to tumor eradication. 4-1BB co-stimulation was administered in the form of the conventional third-generation CAR (GD2.28ζ.CAR). In addition, we constructed vectors encoding both GD2.28ζ.CAR and B7-H3.BBζ.CAR (GD2.28ζ.CAR / B7-H3.BBζ.CAR) simultaneously to produce both bispecificity and bico-stimulation. Both in vitro experiments (Figures 8A-8E) and in vivo experiments (Figures 1E-1H) showed that the bico-CAR obtained with third-generation GD2.28.BBζ.CAR-T cells, and with cleavage co-stimulation of GD2.28ζ.CAR / B7-H3.BBζ.CAR-T cells, did not exhibit superior antitumor activity compared to GD2.28ζ.CAR-T cells under stress conditions. Overall, these data demonstrate that GD2.28ζ.CAR-T cells are most effective in controlling tumor growth at low doses, but do not eradicate tumors under stress conditions. Furthermore, 4-1BB co-stimulation, whether in the form of third-generation CARs or dual CARs, does not enhance the therapeutic effect.
[0077] Dual-targeted CAR-T cells possessing splitting co-stimulation and shared CD3ζ domains exhibit improved expansion, cytokine release, and antitumor activity. We hypothesized that GD2.28ζ.CAR / B7-H3.BBζ.CAR-T cells could receive excessive CAR-CD3ζ signaling, which would impair the beneficial effects of dual costimulation and dual targeting. Therefore, we generated a series of dual CARs encoded in a single retroviral vector to assess whether the shared CAR-CD3ζ chain was sufficient to confer dual antigen specificity and costimulation (Figure 9A).
[0078] A single CAR-CD3ζ domain incorporated into GD2.28ζ.CAR (GD2.28ζ.CAR / B7-H3.BB.CAR), co-expressed with B7-H3.CAR which possesses 4-1BB but lacks a CD3ζ chain, resulted in T cell toxic activity and cytokine release upon engraftment of either GD2.28ζ.CAR or B7-H3.BBζ.CAR (Figures 9B-9C). Therefore, T cells expressing GD2.28ζ.CAR or GD2.28ζ.CAR / B7-H3.BB.CAR were compared in vitro and in vivo. All CARs were well expressed in T cells (Figures 2A-2B), and no alteration of cell subset composition was observed (Figures 9D-9E). In repeated multi-round co-culture experiments of NB tumor cells (Figure 2C), T cells expressing GD2.28ζ.CAR / B7-H3.BB.CAR continued to eliminate NB cells in the fourth round of co-culture compared to T cells expressing GD2.28ζ.CAR alone (Figures 2D, 2H). In addition, T cells expressing GD2.28ζ.CAR / B7-H3.BB.CAR showed the highest T cell counts (Figures 2E, 2I) and the highest IFN-γ and IL-2 release (Figures 2F-2G, 2J-K) in the third and fourth rounds of co-culture. In CHLA-255-carrying NSG mice, T cells expressing GD2.28ζ.CAR / B7-H3.BB.CAR not only demonstrated excellent antitumor activity, eliminating primary tumors under stress conditions, but also controlled tumor growth upon tumor re-administration, thus leading to improved survival rates (Figures 2L-2O). On day 14, mice treated with T cells expressing GD2.28ζ.CAR / B7-H3.BB.CAR showed the highest frequency of circulating T cells (Figure 2P), and on day 28, they continued to show a higher frequency of circulating T cells (Figure 2Q). T cells expressing GD2.28ζ.CAR / B7-H3.BB.CAR are CD4 + T cells and CD8 + CD27 in both T cells + CD28 +The cells were enriched (Figures 11A-11B) and showed low expression of PD-1 and TIM3 (Figures 11C-11D). Overall, these data suggest that dual CAR targeting, splitting signaling, and a single CD3ζ domain promote sustained survival and antitumor effects of CAR-T cells.
[0079] Dual targeting, fragmented signaling, and a single CD3ζ domain promote a sustained T cell activation profile and metabolic compatibility. RNASeq analysis was performed to investigate the extent to which the addition of B7-H3.BB.CAR to GD2.28ζ.CAR enhances the antitumor activity and persistence of CAR-T cells. In the absence of CAR association, T cells with GD2.28ζ.CAR / B7-H3.BB.CAR exhibited a different gene expression pattern compared to T cells expressing GD2.28ζ.CAR alone (Figure 3A). Gene set enrichment analysis (GSEA) showed that glycolysis and IFN-γ signaling were enhanced in T cells expressing GD2.28ζ.CAR / B7-H3.BB.CAR (Figures 3B-3C). Since both glycolysis and IFN-γ pathways are activated by TCR signaling, the dataset was tested using a T cell activation gene set. The transcriptome of T cells expressing GD2.28ζ.CAR / B7-H3.BB.CAR shows a high enrichment of genes upregulated upon T cell activation, while genes downregulated upon T cell activation are enriched in GD2.28ζ.CAR-expressing cells, compared to GD2.28ζ.CAR (Figure 3D and Figures 12A-12C). These data indicate that GD2.28ζ.CAR / B7-H3.BB.CAR-T cells have a higher basal level of TCR activation signaling, occurring in parallel with enhanced phosphorylation of CAR-CD3ζ chains and downstream signaling kinases, such as ERK and Akt (Figure 12D). It has been previously reported that basal CAR-CD3ζ phosphorylation in CAR-T cells encoding the CD28 endodomain promotes stronger and more sustained activation of CAR crosslinking. 28Here, we observed that this effect was further amplified in T cells expressing GD2.28ζ.CAR / B7-H3.BB.CAR compared to T cells expressing GD2.28ζ.CAR (Figure 12E).
[0080] Despite dramatic differences in transcriptomes in the basal resting state, initial CAR-mediated stimulation equally activated T cells expressing either GD2.28ζ.CAR / B7-H3.BB.CAR or GD2.28ζ.CAR, as the transcriptome profiles of T cells with either CAR converged on day 1 (Figure 3E). However, upon discontinuation of antigen stimulation, gene expression differed between T cells expressing GD2.28ζ.CAR / B7-H3.BB.CAR and those expressing GD2.28ζ.CAR on day 5 (Figure 3F), with GD2.28ζ.CAR / B7-H3.BB.CAR-expressing T cells showing enrichment in cell cycle and TCR signaling pathways, suggesting sustained proliferation upon antigen removal (Figures 3G-3H).
[0081] Principal component analysis was performed to determine the relative relationships between the transcriptomes of CAR-T cells on days 0, 1, and 5 (Figure 3I). The variance of the dataset transcripts showed a dominance of CAR activation, which is recorded on PC1 (x-axis). On days 0 and 5, T cells expressing GD2.28ζ.CAR / B7-H3.BB showed higher PC1 scores compared to T cells with GD2.28ζ.CAR, consistent with the results of studies on active TCR signaling. On day 5, the transcriptome of CAR-T cells did not overlap with that of day 0 and clustered to the left of the day 0 CAR-T cells on the PC1 axis, suggesting that these activated and resting T cells enter an "inactivated" state. Notably, T cells expressing GD2.28ζ.CAR / B7-H3.BB acquired further transcriptome differences from T cells expressing GD2.28ζ.CAR, which are recorded on PC2 (y-axis). KEGG pathway analysis of the top 100 highest-loading genes in PC2 revealed that the "cell cycle pathway" was the most enriched (Figure 12F). Consistent with the enrichment of cell cycle-related pathways, T cells expressing GD2.28ζ.CAR / B7-H3.BB.CAR showed sustained T cell proliferation on day 6 after CAR crosslinking (Figure 3J), and a significant expansion, indicated by nearly double the T cell count compared to T cells expressing GD2.28ζ.CAR on day 6 (Figure 3K). Metabolic analysis revealed that T cells expressing GD2.28ζ.CAR / B7-H3.BB.CAR showed increased glycolytic activity compared to T cells expressing GD2.28ζ.CAR on days 0 and 5 post-stimulation. However, only a slight difference was observed on day 1, when activation signaling was at its peak for T cells expressing either GD2.28ζ.CAR / B7-H3.BB.CAR or GD2.28ζ.CAR (Figure 3L). Surprisingly, the enhanced glycolysis observed in T cells expressing GD2.28ζ.CAR / B7-H3.BB.CAR was maintained by the 4-1BB endodomain, in line with the previously described OXPHOS-promoting metabolic profile. 29This was not disrupted because these cells showed a significant increase in oxygen consumption rate before or after CAR stimulation compared to T cells expressing GD2.28ζ.CAR (Figure 3M). Overall, transcriptional analysis, T cell signaling, and metabolism suggest that dual targeting, splitting signaling, and a single CD3ζ domain maintain tonic TCR signaling and metabolic compatibility in T cells, resulting in potent and sustained antitumor activity.
[0082] Dual targeting, fragmented signaling, and a single CD3ζ endodomain prevent antigen evasion. To evaluate whether T cells expressing GD2.28ζ.CAR / B7-H3.BB.CAR prevent tumor evasion due to antigen deficiency, heterogeneous GD2 expression levels in NB cells were utilized. T cells expressing either GD2.28ζ.CAR or GD2.28ζ.CAR / B7-H3.BB.CAR were co-cultured with the NB cell line SH-SY5Y, which contains cells with weak GD2 expression (Figure 4A). T cells expressing GD2.28ζ.CAR / B7-H3.BB.CAR showed the highest antitumor effect (Figure 4B) and Th1 cytokine release (Figures 4C-4D). Next, T cells expressing GD2.28ζ.CAR / B7-H3.BB.CAR were evaluated to determine whether they could prevent tumor evasion in vivo. In a low tumor-load model using SH-SY5Y-carrying NSG mice (Figure 4E), T cells expressing GD2.28ζ.CAR / B7-H3.BB.CAR completely controlled tumor growth (Figures 4F-4H). In mice treated with GD2.28ζ.CAR-expressing T cells, growing tumors showed weaker GD2 expression compared to control mice treated with CD19-specific CAR-T cells, but B7-H3 expression remained unchanged (Figure 4I). Furthermore, T cells expressing GD2.28ζ.CAR / B7-H3.BB.CAR effectively controlled tumor growth in mice treated with higher tumor loads (Figures 13A-13C). Overall, these data suggest that T cells expressing a dual-targeted CAR with a split-costimulatory signal and a single CAR-CD3ζ domain can prevent tumor evasion resulting from the selection of tumor cells with weak antigen expression.
[0083] Consideration Preventing tumor evasion due to heterogeneous antigen expression and providing optimal T cell costimulation remain crucial aspects of obtaining clinical responses with CAR-T cells in solid tumors. Here, we generated CAR-T cells that simultaneously target two antigens and exhibit optimal costimulation and T cell metabolic compatibility by independently activating the CD28 and 4-1BB pathways and regulating CD3ζ chain-mediated signaling. In a clinically significant model of NB, T cells expressing dual CARs exhibited robust and sustained antitumor activity under in vivo stress conditions and prevented tumor evasion due to heterogeneous antigen expression by tumor cells.
[0084] Targeting GD2 with CAR-T cells has significant clinical potential in non-biotropic diseases (NBs). 15、17、24、30 While this approach has proven safe, the ideal co-stimulation of GD2-specific CAR-T cells in a clinical setting remains unclear. In particular, recent clinical studies at Baylor College of Medicine have shown that third-generation CARs encoding both the CD28 and OX40 end-domains, when combined with checkpoint blockade, demonstrate only minimal clinical efficacy. 15 Furthermore, while GD2 is widely recognized as an ideal target for immunotherapy of NB, its heterogeneous expression in tumor cells is not well understood, and the selection of tumor clones with low GD2 expression can lead to tumor recurrence. 31~34 A second clinically significant NB target, represented by B7-H3, has been added. 19 Notably, since GD2 and B7-H3 are physiologically expressed by NB, we investigated the possibility of simultaneously targeting these antigens on tumor cells that naturally express them, as this indicates the physiological density of antigen expression in tumor cells.
[0085] The data demonstrate that it is possible to include two nearly complete CAR sequences targeting two different antigens in a single retroviral vector, and that functional expression levels of both CARs can be obtained in T cells. The first striking observation made was that T cells expressing two CARs, each providing transactive CD28 and 4-1BB endodomains and each possessing its own CD3ζ chain, showed no beneficial effect under in vivo stress conditions. In striking contrast, T cells expressing the same two CARs, each provided with a CD3ζ chain by a single CAR, not only exhibited the cytotoxic effects of each CAR but also elicited a significant antitumor effect in vivo compared to single targeting under stress conditions. The observation that a CAR lacking its own CD3ζ chain can still produce a cytolytic effect on T cells when a second complete CAR is also expressed likely represents a unique characteristic of the synapses formed by CAR molecules. CARs lacking CD3ζ, despite associating with antigens, are unable to effectively utilize the endogenous CD3ζ chain, but can efficiently utilize the CD3ζ chain of bystander CARs expressed by the same cells. Furthermore, this observation aligns with attempts to modulate CAR-T cell activity by modulating CAR-CD3ζ-mediated signaling levels, suggesting that two fully functional CAR-CD3ζ chains can promote excessive signaling in a dual-CAR configuration. 28、35 .
[0086] A second observation made is that the CD28 and 4-1BB pathways, which are trans-activated and independently activated by two distinct CARs, are more effective than the classical in-cis expression of third-generation CARs. This is reminiscent of the proposed approach for supplying the 4-1BB ligand to CAR-T cells encoding CD28. 14However, while CAR-T cell expression of 4-1BB ligand promotes crosstalk between T cells by associating with 4-1BB, the proposed approach has the significant advantage of independently inducing optimal co-stimulation in each individual CAR-T cell when they encounter tumor cells. Furthermore, this approach allows for the targeting of two tumor-associated antigens that prevent tumor evasion.
[0087] The optimal stretch of co-stimulation induced by split co-stimulation and bispecific CARs with a single CD3ζ chain is supported by signaling, molecular, and metabolic properties. Sustained phosphorylation of CAR-neighboring signaling molecules induced by the CD28 endodomain has been demonstrated to lead to imprinting in CAR-T cells that promotes rapid antitumor effects. 10、28、36 In contrast, 4-1BB signaling in CAR-T cells results in metabolic compatibility characterized by oxidative metabolism essential for maintaining CAR-T cell persistence. 29 The CAR-T cells representing the proposed CAR design are characterized by sustained CAR-neighbor signaling, a molecular signature consistent with TCR tonic signaling, and a metabolic profile that yields rapid effector function via glycolysis while retaining oxidative function for long-term persistence.
[0088] In summary, we designed strategies to simultaneously address the most challenging tasks in solid tumors, such as generating CAR-T cells that rapidly eliminate tumors and functionally control tumor growth upon tumor re-administration. Furthermore, these strategies prevent tumor relapse caused by the emergence of tumor cells characterized by low antigen expression.
[0089] material and method Cell lines and cell cultures Human NB cell lineage IMR-32 was purchased from the American Type Culture Collection. Human NB cell lineage CHLA-255 and firefly luciferase (FFLuc)-CHLA-255 were donated by Dr. Metelitsa of Baylor College of Medicine (Houston, TX), and LAN-1 was donated by Dr. Brenner of Baylor College of Medicine (Houston, TX). 20、21 The SH-SY5Y was a donation from Dr. Chiarle of Boston Children's Hospital (Boston, MA). 22 CHLA-255 and LAN-1 were cultured in RPMI-1640 (Gibco, Invitrogen) supplemented with 10% fetal bovine serum (Sigma), 2 mM GlutaMAX (Gibco), 100 units / mL penicillin (Gibco), and 100 μg / mL streptomycin (Gibco). SH-SY5Y were cultured in DMEM (Gibco) supplemented with 10% fetal bovine serum (Sigma), 2 mM GlutaMAX (Gibco), 100 units / mL penicillin (Gibco), and 100 μg / mL streptomycin (Gibco). Cells were maintained at 37°C in a humidified atmosphere containing 5% CO2. Previously described 23 Tumor cells were transduced with gamma retroviral vectors encoding highly sensitive green fluorescent protein (eGFP) and / or the FFLuc gene. All cell lines were mycoplasma-free, and surface markers and functional readout were validated by flow cytometry as needed.
[0090] Plasmid construction A modified GD2-specific single-stranded variable fragment (14G2a, scFv), a GD2-specific CAR encoding the CD8α-Stork and transmembrane domains, the CD28 or 4-1BB intracellular domain, and the CD3ζ intracellular signaling domain was cloned into the retroviral vector SFG backbone. The modified 14G2a scFv is a previously described 24 A B7-H3 specific CAR encoding 376.96 scFv, CD8α-Stork and transmembrane domains, CD28 or 4-1BB intracellular domain, and CD3ζ intracellular signaling domain was cloned into the retroviral vector SFG backbone. 19 A CD19-specific CAR encoding FMC63 scFv, CD8α-Stork and transmembrane domain, CD28 intracellular domain, and CD3ζ intracellular signaling domain was cloned into the retroviral vector SFG backbone. 25 Using a 2A sequence peptide, a vector cassette encoding 14G2a scFv, CD8α-stalk and transmembrane domain, CD28 intracellular domain, and CD3ζ intracellular signaling domain was generated by gene synthesis (GeneArt, Thermo Scientific) in combination with 376.96 scFv, CD8α-stalk and transmembrane domain, and 4-1BB intracellular domain, and cloned into the retroviral vector SFG backbone.
[0091] Retrovirus preparation, transduction and expansion of human T cells. The retroviral supernatant used for transduction of human T cells was prepared as previously described. 23 To put it simply, 2 × 10 6293T cells were seeded in 10 cm culture dishes and transfected with a retroviral transfer vector and a plasmid mixture of the Peg-Pam-e plasmid encoding MoMLV gag-pol and the RDF plasmid encoding the RD114 envelope using GeneJuice transfection reagent (Navagen) according to the manufacturer's instructions. The supernatant containing the retrovirus was collected 48 and 72 hours after transfection and filtered through a 0.45 μm filter. Buffy coat from a healthy donor was purchased from Gulf Coast Regional Blood Center, Houston, TX. Peripheral blood mononuclear cells (PBMCs) isolated by Lymphoprep density separation (Fresenius Kabi Norge) were activated on plates coated with 1 μg / mL CD3 (Miltenyi Biotec) and 1 μg / mL CD28 (BD Biosciences) agonist monoclonal antibodies (mAbs). On the second day, T lymphocytes were transduced with retroviral supernatant using retronectin-coated plates (Takara Bio). Briefly, non-tissue culture-treated 24-well plates were coated with 7 μg / mL retronectin overnight in a refrigerator, washed once with 1 mL of culture medium, coated each well with 1 mL of retroviral supernatant, and centrifuged at 2,000 g for 90 minutes. After removing the supernatant, 5 × 10⁴ cells were extracted. 5Activated T cells were seeded and centrifuged at 1,000 g for 10 minutes. After 3 days, T cells were collected and expanded in complete medium (45% RPMI-1640 and 45% Click Medium (Irvine Scientific), 10% Hyclone FBS (HyClone), 2 mM GlutaMAX (Gibco), 100 units / mL penicillin (Gibco) and 100 μg / mL streptomycin (Gibco), and IL-7 (10 ng / mL; PeproTech) and IL-15 (5 ng / mL; PeproTech)) with medium changes every 2-3 days. On days 12-14, cells were collected for in vitro and in vivo experiments. T cells were cultured in IL-7 / IL-15 depleted medium for 2 days before use in in vitro functional assays. 26 .
[0092] Western blot analysis Protein lysates were normalized according to the percentage of CAR expression and the number of T cells, and resuspended in 2× Laemelli buffer (Bio-Rad) under reducing conditions (using β-mercaptoethanol). To assess CAR signaling, T cells on ice were incubated for 20 minutes with 2 μg of 1A7 anti-idiotype mAb specific to 14G2a scFv and 1 μg of 4Ig-B7-H3 (Chimerigen Laboratories) fused with mouse Fc, and then incubated for a further 20 minutes with 2 μL of goat anti-mouse secondary Ab (BD Bioscience). The cells were then transferred to a 37°C water bath at the indicated time points and lysed in 2× Laemelli buffer. All lysates were separated in 4–15% sodium dodecyl sulfate polyacrylamide gel (SDS-PAGE, Bio-Rad) and transferred to polyvinylidene diflouride membrane (Bio-Rad). After protein transfer to polyvinylidene difluoride membranes, the membranes were blocked with 5% skim milk in Tris buffer saline, 0.1% Tween® 20 (TBST), and incubated with primary antibodies at a 1:1,000 dilution in TBST containing 5% skim milk. The following antibodies were used: anti-CD3ζ (phospho Y142) (Abcam), anti-CD3ζ (Santa Cruz Biotechnology), anti-phospho-p44 / 42 MAPK (Thr202 / Try204) (Cell Signaling), anti-ERK (general) (BD Biosciences), anti-phospho-Akt (Ser473) (Cell Signaling), and anti-Akt (general) (Cell Signaling).Next, the membranes were incubated with HRP-conjugated goat anti-mouse or goat anti-rabbit IgG (both from Santa Cruz) at a dilution of 1:3,000, and colored using SuperSignal West Femto Maximum Sensitivity Substrate or SuperSignal West Pico Chemiluminescent Substrate (both from Thermo Scientific) in a gel station (Boi-Rad).
[0093] Enzyme-linked immunosorbent assay (ELISA) Culture supernatants were collected after 24 hours of co-culture, and IFN-γ and IL-2 release was measured using specific ELISA kits (R&D systems) according to the manufacturer's instructions. Each supernatant was analyzed in a double-row system. Samples were analyzed using a Synergy 2 Multi-Detection Microplate Reader and Gen5 software (both from BioTek).
[0094] Flow cytometry Flow cytometry was performed using acetylcholinethrin (PE), PE-Cy7, fluorescein isothiocyanate (FITC), allophycocyanin (APC), APC-H7, Alexa Fluor 647 (AF 647), brilliant violet (BV) 421, BV510, BV605 and / or BV711-specific antibodies (Abs) specific to human CD3, CD4, CD8, CD27, CD28, CD45, CD45RA, CCR7, PD-1, LAG-3, TIM-3, B7-H3 (clone 7-517), and GD2 (clone 14G2a) (all from BD Biosciences). Human B7-H3 expression in tumor cell lines was assessed using 376.96 mAb and confirmed with another B7-H3 Ab clone 7-517 (BD Biosciences) (Imai et al., 1982). To detect CD19.CAR, a CD19 scFv-specific anti-idiotype mAb (clone 233-4A) was used, followed by either APC or PE-conjugate rat anti-mouse IgG secondary antibody mAb (BD Biosciences). To detect GD2.CAR, a 14G2a scFv-specific 1A7 anti-idiotype mAb (Pule et al., 2005) was used, followed by either APC or PE-conjugate rat anti-mouse IgG secondary mAb (BD Biosciences). Recombinant human B7-H3 Fc chimeric protein (R&D systems) was used, followed by the detection of B7-H3.CAR expression using the Alexa Fluor 647 conjugate AffiniPure F(ab')2 fragment goat anti-human IgG(H+L) secondary mAb (Jackson ImmunoResearch). Samples were analyzed using CountBright absolute counting beads (Thermo Scientific) for absolute count calculations. Samples were analyzed using BD FACScanto II or BD FACSfortessa (BD Biosciences) and BD Diva software (BD Biosciences), acquiring a minimum of 10,000 events for each sample, and the data were analyzed using Flowjo 10 (Tree Star).For a carboxyfluorescein diacetate succinimidyl (CSFE)-based proliferation assay, T cells were labeled with 1.5 mM CSFE (Invitrogen) and seeded with tumor cells in a 1:1 T cell-to-tumor cell ratio. On day 5, T cells were gated using flow cytometry and CSFE dilution was measured. 27 .
[0095] Long-term in vitro cytotoxicity and repeated co-culture assays The day before adding T cells, tumor cells were placed in 24-well plates in 5 × 10⁶ rows. 5 Cells were seeded at a cell / well concentration. Donor-matched T cells, normalized for transduction efficiency, were added at a 1:5 T cell-to-tumor cell ratio without the addition of exogenous cytokines. Cells were collected on day 5 of co-culture, and the frequencies of T cells and residual tumor cells were measured by flow cytometry based on CD3 and GFP expression, respectively. The supernatant was also collected 24 hours after the start of each cycle for cytokine measurement. CD19.28ζ.CAR-T was used as a negative control in each experiment. T cells were identified by CD3 expression and tumor cells by GFP expression, while dead cells were gated out by Zombie Aqua Dye (Biolegend) staining.
[0096] For multiple co-culture rounds, tumor cells were placed in 24-well plates at a rate of 5 × 10⁶ per well the day before T cell addition. 5 Seeds were seeded. Donor-matched T cells, normalized for transduction efficiency, were added in a T cell to tumor cell ratio of 1:5. All T cells were harvested on days 4, 6, and 8, and 5 × 10⁶ cells were collected. 5 NB cells were transferred to new wells seeded the day before T cells were added. After 4 cycles (days 4, 6, 8, and 12), T cells (CD3) were identified by flow cytometry using CountBright absolute counting beads (Thermo Scientific). + ) and NB cells (GFP +These were quantified based on CD3 and GFP expression, respectively. The supernatant was also collected 24 hours after the start of each cycle for cytokine measurement. CD19.28ζ.CAR-T cells were used as a negative control in each experiment. T cells were identified by CD3 expression and tumor cells by GFP expression, while dead cells were gated out by Zombie Aqua Dye (Biolegend) staining.
[0097] Antigen density assay QIFIKIT (Dako, Denmark) was used according to the manufacturer's instructions for use to quantify GD2 and B7-H3 on NB cells. Briefly, cell-bound mAbs were measured by quantitative flow cytometry using mAb-coated beads calibrated to 787,000 molecules, which were used as an internal standard in indirect analysis from background levels. NB cells were incubated for 30 minutes at 4°C with or without 5 μg of either GD2 Ab (clone 14G2a) or B7-H3 Ab (clone 376.96). After washing twice with DPBS / 2 mM EDTA / 2% FBS, NB cells were incubated for 30 minutes at 4°C with a 1:50 dilution of F(ab')2, a fragment of FITC conjugate goat anti-mouse immunoglobulin. After washing once with DPBS (Corning) / 2 mM EDTA (Thermo Scientific) / 2% FBS (HyClone), mAb calibration beads (100 μL / tube) were incubated for 30 minutes at 4°C with a 1:50 dilution of F(ab')2, a fragment of FITC conjugate goat anti-mouse immunoglobulin. After two washes, NB cells and standard beads were resuspended in 300 μL of DPBS / 2 mM EDTA / 2% FBS and analyzed by flow cytometry. The beads were used to construct calibration curves obtained by plotting the average fluorescence intensity against the number of mAb molecules after correcting for the average background fluorescence. The average number of bound mAb molecules per cell was calculated from the average fluorescence intensity using a linear regression curve equation.
[0098] Quantitative polymerase chain reaction in reverse transcription Cells were lysed, RNA was extracted using the RNeasy Minikit (Qiagen), and reverse transcribed into cDNA (Superscript VILO, Invitrogen). Human IFN-γ, CXCL10, IFIT1, IRF7, TCF7, DUSP4, KLRG1, CD300A, and GZMB mRNA expression was quantified using TaqMan probes (Thermo Scientific) on a QuantStudio 6 PCR machine (Applied Biosystems) with 18S ribosomal RNA (Invitrogen) as a housekeeping gene control.
[0099] RNA sequencing analysis In short, total RNA was extracted from CAR-T cells, an mRNA library was prepared (TruSeq Stranded mRNA Library Prep, Illumina), and sequencing was performed on an Illumina HiSeq4000 platform (UNC High-Throughput Sequencing Facility) using paired-end 100bp reads, with an average of 84,000,000 reads (range, 49,000,000 to 139,000,000). The RNA-seq data were aligned with STAR alignment (v2.4.2) and quantified using Salmon (v0.6.0). Differential gene expression analysis was performed using the R DESEq2 package (https: / / genomebiology.biomedcentral.com / articles / 10.1186 / s13059-014-0550-8). Among all significantly expressed genes (FDR p≦0.05) between GD2.28ζ-CAR-T cells and GD2.28ζ+B7-H3.BB.CAR-T cells, further filtering was performed to obtain genes contained in IFN-γ and pathway signatures.
[0100] CAR-T cell activation for RNA-seq, qPCR, and cellular metabolic assays 1 mg / mL of 1A7 anti-idiotype mAb specific to 14G2a scFv and 1 μg / mL of 4Ig-B7-H3 (Chimerigen Laboratories) fused with mouse Fc were coated onto 24-well plates treated with non-tissue culture in a refrigerated room for 16 hours. After washing the plates three times with DPBS (Corning), T cells (1 × 10⁶) were added to the plates. 6 Cells were seeded (per well). CAR-T cells were incubated at 37°C for 24 hours on 1A7 mAb and 4Ig-B7-H3 coated plates. CAR-T cells were then transferred to 24-well tissue culture plates. T cell metabolism was measured using a Seahorse XFe24 analyzer (Seahorse Bioscience). 5 × 10⁶ cells were added to Seahorse BASE medium containing additives in the 24-well Seahorse XF-24 assay plates. 5 T cells were seeded. The cells were incubated at 37°C in a non-CO2 incubator for 45 minutes. All media were adjusted to pH 7.4 on the day of the assay. Mitochondrial and glycolysis stress tests were performed according to the manufacturer's protocol. Oxygen consumption rate and extracellular acidification rate were automatically calculated and recorded using Seahorse XF-24 software.
[0101] Xenotransplant NB mouse model The mouse experiments were conducted in accordance with the University of North Carolina (UNC) Animal Husbandry Guidelines and the protocols approved by the UNC Animal Experimentation Committee. For these studies, 7-10 week old female NSG mice (NOD.Cg-Prkdc) were used. scid IL2rg tm1Wj1 2 × 10⁻¹⁰ via tail vein to / SzJ, UNC Animal Studies Core Facility) 6 FFLuc-CHLA-255, 4×10 6 FFLuc-LAN-1, 0.5×10 6 or 1 × 10 6FFLuc-SH-SY5Y was administered intravenously. Tumor growth was monitored by bioluminescence imaging using the IVIS Lumina II in vivo imaging system (PerkinElmer). For this study, tumor cells resuspended in 200 μL of DPBS (Corning) were intravenously injected via the tail vein using a 28-gauge needle. 14–21 days after tumor cell injection, 2 or 6 × 10⁶ cells were administered. 6 CAR-positive T cells were intravenously injected via the tail vein. To inject the same number of T cells into each mouse, the total T cell count was adjusted to the maximum number by adding non-transduced T cells. Blood was collected from the mice at specific intervals (10-15 days, according to UNC-IACUC guidelines) to measure T cell frequency and / or phenotype. Mice were euthanized if signs of discomfort were detected by the researchers or at the recommendation of a veterinarian who monitored the mice three times a week. At the time of euthanasia, blood, spleen, and / or bone marrow were isolated and analyzed to detect CAR-T cells. In tumor re-administration experiments, tumor-bearing mice were further intravenously injected via the tail vein with FFLuc-CHLA-255 cells, FFLuc-LAN-1, or FFLuc-SH-SY5Y.
[0102] statistical analysis Data are reported as mean values. Differences between two groups were measured using an unpaired, nonparametric Mann-Whitney test and two-sided p-value calculation. For multiple group comparisons, one-way or two-way ANOVA was used to determine statistical significance between samples. A p-value < 0.05 corrected by Tukey's multiple comparison test indicates a significant difference. Measurements were summarized as mean ± SEM as described in the figure captions. The difference between tumor bioluminescence and survival curves was analyzed using the chi-square test with GraphPad Prism v8. The number of experimental samples (n) is shown in the figure captions. The aggregate analysis method is also described in the individual figure captions. Graph generation and statistical analysis were performed using GraphPad Prism software.
[0103] (Example 2) This embodiment presents certain data from Example 1 and provides additional data.
[0104] result Single or dual targeting does not eradicate tumors under stress conditions. Using NB as a tumor model, specifically two tumor cell lines (CHLA-255 and LAN-1) co-expressing two targetable antigens, GD2 and B7-H3, as assessed by flow cytometry (Figure 22A). T cells engineered to express GD2.28ζ, GD2.BBζ, B7-H3.28ζ, and B7-H3.BBζ CARs effectively eliminated tumor cells in vitro without any significant difference (Figures 22C-22E). The cytolytic activity of CAR-T cells was confirmed by the release of IFN-γ and IL-2 into the culture supernatant (Figures 22F-22G) and by the proliferation of T cells in response to the NB cell line (Figure 22H). GD2.28ζ, GD2.BBζ, B7-H3.28ζ, and B7-H3.BBζ CAR-T cells are high-dose CAR-T cells (6 × 10⁻¹⁰). 6 When CAR-T cells were used, tumor growth was controlled in NSG mice engrafted with CHLA-255 (Figures 23A-23D). In stark contrast, stress conditions, such as 2 × 10⁶ CHLA-255-carrying mice, controlled tumor growth. 6 When CAR-T cells were used under stress conditions treated with CAR-T cells (Figure 14A), GD2.28ζ CAR-T cells showed superior tumor control compared to GD2.BBζ, B7-H3.28ζ, and B7-H3.BBζ CAR-T cells (Figures 14B-14D). Similar results were observed in a second NB model in which LAN-1 cells were engrafted in mice (Figures 23E-23H). GD2.28ζ CAR-T cells did not completely eradicate tumors at low doses but showed the most significant antitumor activity, so the addition of 4-1BB costimulation was tested, which was previously described. 11We investigated whether this would lead to tumor eradication. 4-1BB co-stimulation was administered in the form of a third-generation CAR (GD2.28.BBζ). Using two independent CAR molecules, we constructed vectors encoding both the GD2.28ζ CAR and the B7-H3.BBζ CAR (GD2.28ζ / B7-H3.BBζ) simultaneously to yield both bispecificity and bico-stimulation. Both in vitro (Figure 24) and in vivo (Figures 14E-14H) experiments showed that GD2.28.BBζ and GD2.28ζ / B7-H3.BBζ CAR-T cells did not exhibit superior antitumor activity compared to GD2.28ζ CAR-T cells under stress conditions. Overall, these data demonstrate that GD2.28ζ CAR-T cells are most effective in controlling tumor growth at low doses, but do not eradicate tumors under stress conditions. Furthermore, 4-1BB co-stimulation, whether offered in the form of a third-generation CAR or a dual-CAR, does not enhance the therapeutic effect.
[0105] One shared CD3ζ induces dual CAR-T cells. We hypothesized that GD2.28ζ / B7-H3.BBζ CAR-T cells could receive excessive CD3ζ signaling that impairs the beneficial effects of dual targeting and dual costimulation. A series of dual CARs encoded in a single retroviral vector were generated to assess whether the shared CD3ζ chain was sufficient to provide optimal activation signaling for dual antigen targeting, as well as the respective roles of single antigen recognition and costimulation in dual targeting (Figure 15A). As expected, GD2.28ζ, GD2.28ζ / B7-H3.BB, and GD2.28ζ / dNGFR.BB CAR-T cells, expressing fully functional GD2.CAR, were found to recognize tumor cells. Similarly, B7-H3.BBζ CAR-T cells, expressing fully functional B7-H3.CAR, recognized tumor cells, while B7-H3.BB CAR-T cells, lacking CD3ζ in this CAR, did not recognize tumors (Figures 15B-15E). Surprisingly, B7-H3.BB CAR-T cells acquired cytolytic activity and cytokine lysis when co-expressing either dNGFR.28ζ or 28ζ. +It was found to be released towards tumor cells (Figures 15B-15E). This indicates that the incomplete B7-H3.BB CAR, which associates with the antigen, can utilize CD3ζ expressed in cis, provided by another portion that does not directly recognize the antigen. Furthermore, when B7-H3.BB.CAR was co-expressed with GD2.28ζ CAR, and when the two CARs associated with their respective antigens simultaneously, CAR-T cells released significantly higher levels of cytokines compared to GD2.28ζ CAR-T cells. This indicates that an additional co-stimulatory effect is mediated by 4-1BB (Figures 15D-15E). In T cells co-expressing GD2.28ζ CAR and dNGFR.BB, which inhibits B7-H3 association, the additional effect of 4-1BB on promoting more cytokine release was abolished. This indicates that the co-stimulatory effect from 4-1BB is mediated only when both CARs associate with their respective target antigens (Figures 15D-15E).
[0106] To investigate whether two CAR molecules share a single CD3ζ from heterodimers after association with their alloantigens, reducing and non-reducing gel separations and Western blotting were performed. In B7-H3.BB.CAR-T cells co-expressing either the dNGFR.28ζ or 28ζ molecule and stimulated with the B7-H3-Fc protein, which then crosslinks with a secondary anti-Fc antibody, it was found that B7-H3.BB.CAR forms heterodimers or oligomers with the dNGFR.28ζ or 28ζ molecule, but these dimers or oligomers are not observed without antigen stimulation (Figures 16A-16B). Two cysteine residues located at positions 164 and 181 of the CD8α-Stork region are involved in the dimerization of the CAR molecule. 25Therefore, we induced C164S and C181S mutations (CD8m) in the CD8 stalk and investigated whether these two cysteine residues are essential for mediating the dimerization of B7-H3.BB.CAR and dNGFR.28ζ or 28ζ molecules. CAR-T cells manipulated with constructs containing the mutant cysteine residues did not exhibit cytotoxic activity or cytokine release when co-cultured with the CHLA-255 cell line (Figures 16C-16F). To further investigate the role of antigen association in mediating CAR molecule dimerization, we performed co-culture experiments using Raji cells genetically engineered to express B7-H3 but lack GD2 expression (Figure 25A). T cells co-expressing B7-H3.BB.CAR with GD2.28ζ CAR, dNGFR.28ζ, or 28ζ efficiently targeted B7-H3-expressing Raji cells and released IFN-γ and IL-2, but T cells co-expressing GD2.28ζ CAR with dNGFR.BB did not show antitumor activity (Figures 25B-25D). Control co-cultures with wild-type Raji cells also did not show antitumor activity (Figures 25E-25G). This indicates that the cytolytic activity of dual-CAR T cells remains antigen-dependent.
[0107] To investigate whether the two CARs in GD2.28ζ / B7-H3.BB CAR-T cells can cluster at the same immunological synapse upon association with either one of the antigens and subsequently induce activation signals by a shared CD3ζ chain, GFP was fused with GD2.28ζ and co-transduced into T cells with B7-H3.BB. These cells were then stimulated with either or both of the anti-GD2.CAR idiotype antibody 1A7 or the B7-H3-Fc fusion protein. Using confocal microscopy imaging, it was found that the GD2.28ζ and B7-H3.BB CARs co-localize with each other, forming membrane clusters upon CAR crosslinking by single or double CAR association (Figure 16G and Figure 26).
[0108] Dual CAR-T cells show improved function. To evaluate whether 4-1BB costimulation induced by B7-H3.BB CAR enhances the antitumor activity of GD2.28ζ CAR-T cells, the functionality of GD2.28ζ / B7-H3.BB CAR-T cells and GD2.28ζ CAR-T cells was compared both in vitro and in vivo. All CARs were found to be well expressed in T cells (Figures 17A-17B), and no alteration of cell subset composition was observed (Figures 27A-27B). In repeated multi-round co-culture experiments of NB tumor cells (Figure 17C), only GD2.28ζ / B7-H3.BB CAR-T cells continued to eliminate NB cells in the fourth round of co-culture (Figures 17D, 17H). In addition, T cells expressing GD2.28ζ / B7-H3.BB showed the highest T cell counts (Figures 17E, 17I) and the highest IFN-γ and IL-2 release (Figures 17F-17G, 17J-17K) in the third and fourth rounds of co-culture. In CHLA-255-carrying NSG mice, GD2.28ζ / B7-H3.BB CAR-T cells not only demonstrated excellent antitumor activity, eliminating primary tumors under stress conditions, but also controlled tumor growth upon tumor re-administration, thus leading to improved survival rates (Figures 17L-17O). On day 14, mice treated with GD2.28ζ / B7-H3.BB CAR-T cells showed the highest frequency of circulating T cells (Figure 17P), and on day 28, they continued to show a higher circulating T cell rate (Figure 17Q). GD2.28ζ / B7-H3.BB CAR-T cells are CD4 + T cells and CD8 + CD27 in both T cells + CD28 +The cells were enriched and showed low expression of PD-1 and TIM3 (Figures 27C-27F). A dual CAR was also constructed in which B7-H3.CAR possessed CD28 costimulation and CD3ζ, while GD2.CAR contained a 4-1BB costimulation endodomain (B7-H3.28ζ / GD2.BB) lacking CD3ζ (Figure 28A). B7-H3.28ζ / GD2.BB CAR-T cells were found to exhibit superior antitumor activity compared to single B7-H3.28ζ CAR-T cells in in vitro multi-round co-culture experiments with CHLA-255 and LAN-1 tumor cells (Figures 28B-28O), as well as in vivo in a CHLA-255 NB metastatic tumor model (Figure 29).
[0109] To further investigate whether dual targeting, split co-stimulation, and shared CD3ζ may be generally applicable, two additional CARs were used to target mesotheline (MSLN) and chondroitin sulfate proteoglycan 4 (CSPG4), respectively. 22~24 A construct (MSLN.28ζ / CSPG4.BB) was generated that encodes MSLN.CAR, which has CD28 and CD3ζ, and co-expresses CSPG4.CAR, which has a 4-1BB costimulatory domain but lacks CD3ζ (Figure 18A). When T cells expressing MSLN.28ζ, CSPG4.BBζ, CSPG4.BB, and MSLN.28ζ / CSPG4.BB CAR were co-cultured with MSLN and CSPG4 double-positive mesothelioma cell line H2052 (Figure 18B), all CAR-T cells except CSPG4.BB CAR-T cells eliminated tumor cells and released INF-γ and IL-2 (Figures 30A-30E). However, MSLN.28ζ / CSPG4.BB CAR-T cells showed superior antitumor activity compared to single-target CAR-T cells in in vitro multi-round co-culture experiments (Figures 18C-18D and 30F-30H) and in an intraperitoneal metastatic mesothelioma model (Figures 18E-18I). Overall, these data suggest that split-costimulatory signaling and dual CAR targeting at a single shared CD3ζ domain promote the sustained survival and antitumor effects of CAR-T cells.
[0110] T cell activation and metabolic compatibility of dual CAR-T cells RNASeq analysis was performed to investigate the extent to which the addition of the B7-H3.BB CAR to the GD2.28ζ CAR enhances the antitumor activity and persistence of CAR-T cells. In the absence of CAR association, GD2.28ζ / B7-H3.BB CAR-T cells showed a different gene expression pattern compared to GD2.28ζ CAR-T cells (Figures 19A-19B). Gene set enrichment analysis (GSEA) showed that glycolysis and IFN-γ signaling were enhanced in GD2.28ζ / B7-H3.BB CAR-T cells (Figures 19C-19D). Since both glycolysis and IFN-γ pathways are activated by TCR signaling, the dataset was tested using a T cell activation gene set. The transcriptome of CAR-T cells expressing GD2.28ζ / B7-H3.BB is highly enriched with genes upregulated upon T cell activation, while genes downregulated upon T cell activation are enriched in GD2.28ζ CAR-T cells compared to those expressing GD2.28ζ CAR (Figures 19E-19G). These data indicate that GD2.28ζ / B7-H3.BB CAR-T cells have a higher basal level of TCR activation signaling, occurring in parallel with enhanced phosphorylation of CAR-CD3ζ chains and downstream signaling kinases, such as ERK and Akt (Figure 19H). It has been previously reported that basal CAR-CD3ζ phosphorylation in CAR-T cells encoding the CD28 endodomain promotes stronger and more sustained activation of CAR crosslinking. 28Here, we observed that this effect was further amplified in GD2.28ζ / B7-H3.BB CAR-T cells compared to T cells expressing only the GD2.28ζ CAR (Figure 19I). Despite differences in transcriptomes in the basal resting state, initial CAR-mediated stimulation activated T cells expressing either the GD2.28ζ / B7-H3.BB CAR or the GD2.28ζ CAR equally, as the transcriptome profiles of T cells with either CAR converged on day 1 (Figure 20A). However, upon discontinuation of antigen stimulation, gene expression differed between T cells expressing the GD2.28ζ / B7-H3.BB CAR and those expressing the GD2.28ζ CAR on day 5 (Figure 20B). CAR-T cells expressing GD2.28ζ / B7-H3.BB showed enrichment in cell cycle and TCR signaling pathways on day 5, suggesting sustained proliferation upon antigen removal (Figures 20C-20D). Principal component analysis was performed to determine the relative relationships between the transcriptomes of CAR-T cells on days 0, 1, and 5 (Figure 20E). The variance of the dataset transcripts showed a dominance of CAR activation, which is recorded on PC1 (x-axis). On days 0 and 5, GD2.28ζ / B7-H3.BB CAR-T cells showed higher PC1 scores compared to GD2.28ζ CAR-T cells, consistent with the results of studies on active TCR signaling. Notably, CAR-T cells expressing GD2.28ζ / B7-H3.BB acquired further transcriptome differences from T cells expressing GD2.28ζ CAR, which are recorded on PC2 (y-axis). KEGG pathway analysis of the top 100 highest-loading genes in PC2 revealed that the "cell cycle pathway" was the most enriched (Figure 32). Consistent with the enrichment of cell cycle-related pathways, sustained T cell proliferation was observed in GD2.28ζ / B7-H3.BB CAR-T cells 6 days after CAR crosslinking (Figure 20F), showing a favorable expansion, as indicated by nearly double the T cell count at 6 days compared to GD2.28ζ CAR-T cells (Figure 20G).Metabolic analysis showed that CAR-T cells expressing GD2.28ζ / B7-H3.BB exhibited increased glycolytic activity compared to CAR-T cells expressing GD2.28ζ on days 0 and 5 post-stimulation. However, only a slight difference was observed in activation signaling on day 1, which was the peak for T cells expressing either GD2.28ζ / B7-H3.BB CAR or GD2.28ζ CAR (Figure 20H). Surprisingly, the enhanced glycolysis observed in CAR-T cells expressing GD2.28ζ / B7-H3.BB was maintained by the 4-1BB endodomain, as previously described in the OXPHOS-promoting metabolic profile. 29 This did not disrupt the signaling pathway. This is because these cells showed a significant increase in oxygen consumption rate before or after CAR stimulation compared to CAR-T cells expressing GD2.28ζ (Figure 20I). Overall, transcriptional analysis, T cell signaling, and metabolism suggest that dual targeting, splitting signaling, and a single CD3ζ domain maintain tonic TCR signaling and metabolic compatibility in T cells, resulting in potent and sustained antitumor activity.
[0111] Dual CAR-T cells prevent antigen evasion. To evaluate whether GD2.28ζ / B7-H3.BB CAR-T cells prevent tumor evasion caused by variable antigen expression in tumor cells, heterogeneous GD2 expression levels in NB cells were utilized. CAR-T cells expressing either GD2.28ζ or GD2.28ζ / B7-H3.BB were co-cultured with the NB cell line SH-SY5Y, which exhibits heterogeneous GD2 expression (Figures 21A-21B). GD2.28ζ / B7-H3.BB CAR-T cells showed the best antitumor effect (Figure 21C) and Th1 cytokine release (Figures 21D-21E). Next, GD2.28ζ / B7-H3.BB CAR-T cells were evaluated to determine whether the cells could prevent tumor evasion in vivo. In a low tumor-load model using SH-SY5Y-carrying NSG mice (Figure 21F), CAR-T cells expressing GD2.28ζ / B7-H3.BB completely controlled tumor growth (Figures 21G-21I). In mice treated with GD2.28ζ CAR-T cells, growing tumors showed weaker GD2 expression compared to control mice treated with CD19-specific CAR-T cells. In contrast, B7-H3 expression remained unchanged in tumor cells in mice injected with GD2.28ζ CAR-T cells because this antigen was not targeted (Figure 21J). Furthermore, CAR-T cells expressing GD2.28ζ / B7-H3.BB effectively controlled tumor growth in mice treated with higher tumor loads (Figure 31). Overall, these data suggest that T cells expressing a bitargeted CAR with a fragmentation costimulatory signal and a single CD3ζ domain have superior antitumor activity when tumors contain cells with weak target antigen expression, which can lead to tumor evasion from single-targeted CAR-T cell treatment.
[0112] Consideration Preventing tumor evasion due to heterogeneous antigen expression and providing optimal T cell costimulation remain crucial aspects of obtaining clinical responses with CAR T cells in solid tumors. Here, we generated CAR-T cells that simultaneously target two antigens, exhibiting optimal costimulation and T cell metabolic compatibility by independently activating the CD28 and 4-1BB pathways and regulating CD3ζ chain-mediated signaling. In a model of NB, T cells expressing dual CARs exhibited robust and sustained antitumor activity under in vivo stress conditions, preventing tumor evasion due to heterogeneous antigen expression by tumor cells. The beneficial effects of the proposed combination of dual targeting, fragmentation costimulation, and regulated CD3ζ signaling were reproduced using another pair of CAR molecules.
[0113] Targeting GD2 with CAR-T cells has significant clinical potential in non-biotropic diseases (NBs). 17、19、26~28 While this approach has proven safe, the ideal co-stimulation of GD2-specific CAR-T cells in a clinical setting remains unclear. In particular, a recent clinical study at Baylor College of Medicine, using third-generation CARs encoding both the CD28 and OX40 endodomains, demonstrated only minimal clinical efficacy, even when combined with checkpoint blockade. 17 Furthermore, while GD2 is widely recognized as an ideal target for immunotherapy of NB, its heterogeneous expression in tumor cells is not well understood, and the selection of tumor clones with low GD2 expression can lead to tumor recurrence. 29~32 Therefore, a second clinically significant NB target, represented by B7-H3, was added. 21 Notably, since GD2 and B7-H3 are physiologically expressed by NB, we tested the potential to simultaneously target these antigens on tumor cells that naturally express them, indicating the physiological density of antigen expression in tumor cells. Similarly, MSLN is currently being evaluated for treating mesothelioma, lung cancer, breast cancer, pancreatic cancer, and prostate cancer with scFv-based CAR-T cells.33 , its optimal combination with other clinically significant targets such as CSPG4 34、35 It was explored.
[0114] The data demonstrate that it is possible to include two nearly complete CAR sequences targeting two different antigens in a single retroviral vector, and that functional expression levels of both CARs can be obtained in T cells. The first observation made was that T cells expressing two CARs, each providing transactive CD28 and 4-1BB endodomains and each possessing its own CD3ζ chain, showed no beneficial effects under in vivo stress conditions. In striking contrast, T cells expressing the same two CARs, each provided with a CD3ζ chain by a single CAR, not only exhibited cytotoxic effects of each CAR but also induced antitumor effects in vivo compared to single targeting under stress conditions. The observation that a CAR lacking its own CD3ζ chain can still produce a cytolytic effect on T cells when a second complete CAR is also expressed likely represents a unique characteristic of the synapses formed by CAR molecules. CARs lacking CD3ζ, despite associating with antigens, cannot effectively utilize the endogenous CD3ζ chain, but can efficiently utilize the CD3ζ chain of bystander CARs expressed by the same cells. The sharing of the CD3ζ chain to induce T cell activation is strictly mediated by the presence of two cysteine residues in the CD8α-stalk as an essential part of the CAR molecule. Furthermore, CD3ζ chain sharing occurs only upon antigen association, thereby preventing dimerization of the two CARs when neither antigen is associated.
[0115] A second observation made is that the CD28 and 4-1BB pathways, which are trans-activated and independently activated by two distinct CARs, are more effective than the classical in-cis expression of third-generation CARs. This is reminiscent of the proposed approach for supplying the 4-1BB ligand to CAR-T cells encoding CD28. 16However, while the presentation of the 4-1BB ligand to T cells co-expressing 4-1BBL and CAR requires crosstalk between CAR-T cells, the approach described herein has the significant advantage of independently stimulating both 4-1BB and CD28 signaling to each single CAR-T cell when they encounter a tumor. Furthermore, by splitting the co-stimulation to the two CARs, it becomes possible to target two tumor-associated antigens and, to some extent, prevent tumor evasion.
[0116] The optimal stretch of co-stimulation provided by split co-stimulation and bispecific CARs with a single CD3ζ chain is supported by signaling, molecular, and metabolic properties. Sustained phosphorylation of CAR-neighboring signaling molecules induced by the CD28 endodomain has been demonstrated to lead to imprinting in CAR-T cells that promotes rapid antitumor effects. 11、12、36 In contrast, 4-1BB signaling in CAR-T cells results in metabolic compatibility characterized by oxidative metabolism essential for maintaining CAR-T cell persistence. 37 The CAR-T cells representing the proposed CAR design are characterized by potent and sustained CAR-neighbor signaling and a molecular signature consistent with the TCR tonic signal, which are essential for promoting rapid antitumor effects. Similarly, metabolic profiling shows that the dual CAR-T cells exhibit rapid effector function via glycolysis, supported by CD28 signaling, but also retain the oxidative function during antigen removal, characteristic of 4-1BB costimulation, thus supporting memory formation and long-term persistence.
[0117] In summary, we designed a strategy that simultaneously addresses some of the most challenging tasks in solid tumors, such as generating CAR-T cells that rapidly eliminate tumors and continue to control tumor growth upon tumor re-administration. Furthermore, these CAR-T cells prevent tumor recurrence caused by the emergence of tumor cells characterized by low antigen expression.
[0118] material and method Cell lines and cell cultures The human mesothelioma cell lineage H2052 and the human B-cell lymphoma cell lineage Raji were purchased from the American Cell Culture and Cell Lineage Preservation Center (ATCC), and Raji-B7-H3 was generated by transduction of Raji cells with a retrovirus encoding B7-H3. 21 The human NB cell lineage CHLA-255 and firefly luciferase (FFLuc)-CHLA-255 were donated by Dr. Metelitsa of Baylor College of Medicine (Houston, TX) (originally obtained from metastatic brain lesions of patients with relapsed disease at Children's Hospital Los Angeles). 38、39 The LAN-1 was originally purchased by ATCC as a donation from Dr. Brenner of Baylor College of Medicine (Houston, TX). 40、41 The SH-SY5Y was originally purchased by ATCC and donated by Dr. Chiarle of Boston Children's Hospital (Boston, MA). 42 CHLA-255, LAN-1, H2052, and Raji were cultured in RPMI-1640 (Gibco, Invitrogen) supplemented with 10% fetal bovine serum (Sigma), 2 mM GlutaMAX (Gibco), 100 units / mL penicillin (Gibco), and 100 μg / mL streptomycin (Gibco). SH-SY5Y was cultured in DMEM (Gibco) supplemented with 10% fetal bovine serum (Sigma), 2 mM GlutaMAX (Gibco), 100 units / mL penicillin (Gibco), and 100 μg / mL streptomycin (Gibco). Cells were maintained at 37°C in a humidified atmosphere containing 5% CO2. Previously described 43As described above, tumor cells were transduced with a gammaretroviral vector encoding the highly sensitive green fluorescent protein (eGFP) and / or the FFLuc gene. All cell lines were mycoplasma-free and were verified for surface markers and functional readouts by flow cytometry as needed.
[0119] Plasmid construction All retroviral vectors were generated using the SFG backbone. The GD2-specific CAR was generated using the modified GD2-specific single-chain variable fragment (14G2a scFv), CD8α stalk and transmembrane domain, CD28 or 4-1BB intracellular domain, and CD3ζ intracellular domain (GD2.28ζ and GD2.BBζ) as described to correct the previously reported tonic signaling 26 of the scFv. The B7-H3-specific CAR was generated using 376.96 scFv, CD8α stalk and transmembrane domain, CD28 or 4-1BB intracellular domain, and CD3ζ intracellular domain (B7-H3.28ζ and B7-H3.BBζ). 19 The CD19-specific CAR was generated using FMC63 scFv, CD8α stalk and transmembrane domain, CD28 intracellular domain, and CD3ζ intracellular domain (CD19.28ζ). 44Cassettes encoding GD2.28ζ (GD2.28ζ / B7-H3.BB and GD2.28ζ / B7-H3.BBζ) were generated by gene synthesis (GeneArt, Thermo Scientific) in combination with B7-H3.BB CARs having or not having a CD3ζ intracellular domain linked to a 2A sequence peptide. GD2-specific CARs encoding both CD28 and 4-1BB and CD3ζ (GD2.28.BBζ) were generated by gene synthesis (GeneArt, Thermo Scientific). B7-H3.BB.CAR was generated by PCR using B7-H3.BBζ as a template to remove CD3ζ. Cassettes encoding GD2.28ζ and destabilized human neuronal growth factor receptor (dNGFR) with CD8α-stalk and transmembrane domain and 4-1BB intracellular domain were ligated together with a 2A sequence peptide (GD2.28ζ / dNGFR.BB). Cassettes encoding dNGFR, CD8α-stalk and transmembrane domain, CD28 intracellular domain, and CD3ζ in combination with the B7-H3.BB CAR domain were ligated together with a 2A sequence peptide (dNGFR.28ζ / B7-H3.BB). The 28ζ / B7-H3.BB cassette was constructed by removing the 14g2a scFv sequence from GD2.28ζ / B7-H3.BB by PCR. The GD2.BB cassette was constructed by removing CD3ζ from GD2.BBζ by PCR. The B7-H3.28ζ / GD2.BB cassette was constructed by adding GD2.BB to B7-H3.28ζ via gene synthesis (GeneArt, Thermo Scientific), and then ligated with a 2A sequence. The CSPG4.BBζ CAR was constructed by cloning the 763.74 scFv, CD8α stalk and transmembrane domain, 4-1BB intracellular domain, and CD3ζ. 23 The CSPG4.BB cassette was constructed by removing CD3ζ from CSPG4.BBζ by PCR. The MSLN.28ζ CAR was constructed by cloning the scFv, CD8α stalk and transmembrane domain, CD28 intracellular domain, and CD3ζ of amatsuximab. 45The MSLN.28ζ / CSPG4.BB cassette was constructed by inserting CSPG4.BB into the MSLN.28ζ main chain and linking them in a 2A sequence.
[0120] Retrovirus preparation, transduction and expansion of human T cells. The retroviral supernatant used for transduction of human T cells was prepared as previously described. 43 Buffy coat from healthy donors was purchased from Gulf Coast Regional Blood Center, Houston, TX. CAR-T cells were generated using peripheral blood mononuclear cells (PBMCs) isolated by lymphhoprep density separation (Fresenius Kabi Norge). PBMCs were activated on plates coated with 1 μg / mL CD3 (Miltenyi Biotec) and 1 μg / mL CD28 (BD Biosciences) agonist monoclonal antibodies (mAbs). T lymphocytes were transduced on retronectin-coated plates (Takara Bio) and then expanded in complete medium (45% RPMI-1640 and 45% Click Medium (Irvine Scientific), 10% Hyclone FBS (HyClone), 2 mM GlutaMAX (Gibco), 100 units / mL penicillin (Gibco) and 100 μg / mL streptomycin (Gibco), and IL-7 (10 ng / mL; PeproTech) and IL-15 (5 ng / mL; PeproTech)) for 12–14 days, changing the medium every 2–3 days. The T cells were cultured in IL-7 / IL-15 depleted medium for 2 days before use in in vitro functional assays. 46 .
[0121] Western blot analysis Protein lysates were normalized according to the percentage of CAR expression and the number of T cells, and resuspended in 2× Laemelli buffer (Bio-Rad) under reducing conditions (using β-mercaptoethanol). To assess CAR signaling, T cells were placed on ice and incubated for 20 minutes with 2 μg of 1A7 anti-idiotype mAb specific to 14G2a scFv and 1 μg of 4Ig-B7-H3 (Chimerigen Laboratories) fused with mouse IgG2a Fc, and then crosslinked with 2 μL of goat anti-mouse secondary Ab (BD Bioscience) for a further 20 minutes. The cells were then transferred to a 37°C water bath and lysed in 2× Laemelli buffer at the indicated time points. To assess the dimers and oligomers of the two CARs, T cells were placed on ice and incubated for 20 minutes with 1 μg of 4Ig-B7-H3 (Chimerigen Laboratories) fused with mouse IgG2a Fc, followed by a further 20 minutes of incubation with 2 μL of goat anti-mouse secondary Ab (BD Bioscience). The cells were then transferred to a 37°C water bath for 20 minutes and lysed at 100°C for 10 minutes under reducing (using β-mercaptoethanol) or non-reducing (not using β-mercaptoethanol) conditions using 2×Laemelli buffer. All lysates were separated in 4-15% sodium dodecyl sulfate polyacrylamide gel (SDS-PAGE, Bio-Rad) and transferred to polyvinylidene difluoride membrane (Bio-Rad). After protein transfer to polyvinylidene difluoride membranes, the membranes were blocked with 5% skim milk in Tris buffer saline, 0.1% Tween 20 (TBST), and incubated with primary antibodies at a 1:1,000 dilution in TBST containing 5% skim milk. The following antibodies were used: anti-phospho-CD3ζ (Y142) (Abcam), anti-CD3ζ (Santa Cruz Biotechnology), anti-ERK (general) (BD Biosciences), anti-phospho-Akt (Ser473) (Cell Signaling), and anti-Akt (general) (Cell Signaling).Next, the membranes were incubated with HRP-conjugated goat anti-mouse or goat anti-rabbit IgG (both from Santa Cruz) at a dilution of 1:3,000, and colored using SuperSignal West Femto Maximum Sensitivity Substrate or SuperSignal West Pico Chemiluminescent Substrate (both from Thermo Scientific) in a gel station (Boi-Rad).
[0122] Enzyme-linked immunosorbent assay (ELISA) Culture supernatants were collected after 24 hours of co-culture, and IFN-γ and IL-2 release was measured using specific ELISA kits (R&D systems) according to the manufacturer's instructions. Each supernatant was analyzed in a double-row system. Samples were analyzed using a Synergy 2 Multi-Detection Microplate Reader and Gen5 software (both from BioTek).
[0123] Flow cytometry Flow cytometry was performed using human CD3, CD4, CD8, CD27, CD28, CD45, CD45RA, CCR7, PD-1, LAG-3, TIM-3, B7-H3 (clone 7-517), and GD2 (clone 14G2a) (all from BD Biosciences) specific abs conjugated with phycoerythrin (PE), PE-Cy7, fluorescein isothiocyanate (FITC), allophycocyanin (APC), APC-H7, Alexa Fluor 647 (AF 647), brilliant violet (BV) 421, BV510, BV605, and / or BV711. Human B7-H3 expression in tumor cell lines was assessed at 376.96 mAb, and compared with another B7-H3 ab clone 7-517 (BD Biosciences). 47This was confirmed. To detect CD19.CAR, GD2.CAR, and CSPG4.CAR, the CARs were stained using anti-idiotype mAbs 233-4A, 1A7, and MK2-23 as primary Abs, respectively, and then stained using either APC or PE conjugated rat anti-mouse IgG secondary mAb (BD Biosciences). MSLN.CAR has a fusion flag tag, and therefore its expression was detected using an APC conjugated anti-Flag mAb (Clone L5, Biolegend). Recombinant human B7-H3 Fc chimeric protein (R&D systems) was used, followed by the detection of B7-H3.CAR expression using an Alexa Fluor 647 conjugated AffiniPure F(ab')2 fragment goat anti-human IgG(H+L) secondary mAb (Jackson ImmunoResearch). For absolute count calculations, samples were analyzed using CountBright absolute counting beads (Thermo Scientific). Samples were analyzed using BD FACScanto II or BD FACSfortessa (BD Biosciences) and BD Diva software (BD Biosciences), acquiring a minimum of 10,000 events for each sample, and the data were analyzed using Flowjo 10 (Tree Star). For a carboxyfluorescein diacetate succinimidyl (CSFE)-based proliferation assay, T cells were labeled with 1.5 mM CSFE (Invitrogen) and seeded with tumor cells in a 1:1 T cell-to-tumor cell ratio. On day 5, T cells were gated using flow cytometry and the CSFE dilution was measured. 48 .
[0124] Measurement of GD2 antigen density The determination of GD2 antigen density on the cell surface of CHLA-255, LAN-1, and SH-SY5Y was performed using both the DAKO QIFIKIT (BIOCYTEX, Glostrup, Denmark) and primary antibodies specific for GD2 (clone 14G2a) and B7-H3 (clone 376.96). All procedures were carried out according to the manufacturer's recommended protocol. Fluorescence intensity was correlated with the number of bound primary antibody molecules on the surface of the cell line. Antigen density was calculated based on the MFI of stained cells and a standard curve created using the MFI of five populations of beads with different numbers of mouse monoclonal antibody molecules.
[0125] Long-term in vitro cytotoxicity and multi-round co-culture assays One day prior to the addition of T cells, tumor cells were seeded in 24-well plates at a concentration of 5 × 10 5 cells / well. T cells normalized for transduction efficiency were added at a 1:5 T cell to tumor cell ratio without the addition of exogenous cytokines. On day 5 of co-culture, cells were harvested and T cells and tumor cells were measured by flow cytometry based on CD3 and GFP expression, respectively. Supernatants were also collected 24 hours after the start of each cycle for cytokine measurement. CD19.28ζ.CAR-T was used as a negative control. Dead cells were gated out by staining with Zombie Aqua Dye (Biolegend). For multiple co-culture rounds with the NB cell lines of CHLA-255 and LAN-1, tumor cells were seeded in 24-well plates at 5 × 10 5 per well one day prior to the addition of T cells. T cells normalized for transduction efficiency were added at a 1:5 T cell to tumor cell ratio. Four, three, and two duplicates were performed for the first, second, and third rounds of co-culture for each condition, respectively. At the end of each round of co-culture, one duplicate was used to measure residual tumor cells (GFP + ) and T cells (CD3 +To quantify the T cells, they were harvested and collected in other duplicates for use in the next co-culture round. In the co-culture of GD2.28ζ / B7-H3.BB with GD2.28ζ CAR-T cells, T cells were harvested on days 4, 6, and 8 and 5 × 10⁶ were used for the next co-culture round. 5 The NB cells were transferred to new wells seeded the day before T cell addition. In co-culture of B7-H3.28ζ / GD2.BB with B7-H3.28ζ CAR-T cells, T cells were harvested on days 4, 7, and 10 and 5 × 10 for the next co-culture round. 5 NB cells were transferred to new wells seeded the day before T cell addition. The supernatant was also collected 24 hours after T cell addition for cytokine measurement in each co-culture round. For multiple co-culture rounds with mesothelioma cell lineage H2052, tumor cells were seeded 2.5 × 10⁶ per well in a 24-well plate the day before T cell addition. 5 The cells were seeded. T cells normalized for transduction efficiency were added in a 1:5 T cell-to-tumor cell ratio. Two duplicates were used after each round of co-culture. At the end of each round of co-culture on days 5, 9, 13, and 17, residual tumor cells (GFP) were measured by flow cytometry using CountBright absolute counting beads (Thermo Scientific). + ) and T cells (CD3 + One duplicate was collected to examine it. As for the other duplicate, T cells were collected and 1 / 3 were divided into 2.5 × 10⁶ for the next co-culture round. 5 H2052 cells were transferred to new wells seeded the day before T cell addition. The supernatant was also collected 24 hours after T cell addition for cytokine measurement in each co-culture round. CD19.28ζ.CAR-T cells were used as a negative control in each co-culture experiment. T cells were identified by CD3 expression, tumor cells by GFP expression, while dead cells were gated out by Zombie Aqua Dye (Biolegend) staining.
[0126] Quantitative polymerase chain reaction in reverse transcription Cells were lysed, RNA was extracted using the RNeasy Minikit (Qiagen), and reverse transcribed into cDNA (Superscript VILO, Invitrogen). Human DUSP4, KLRG1, CD300A, and GZMB mRNA expression was quantified using a TaqMan probe (Thermo Scientific) on a QuantStudio 6 PCR machine (Applied Biosystems) with 18S ribosomal RNA (Invitrogen) as a housekeeping gene control.
[0127] RNA sequencing analysis In short, total RNA was extracted from CAR-T cells, an mRNA library was prepared (TruSeq Stranded mRNA Library Prep, Illumina), and sequencing was performed on an Illumina HiSeq4000 platform (UNC High-Throughput Sequencing Facility) using paired-end 100bp reads, with an average of 84,000,000 reads (range, 49,000,000 to 139,000,000). The RNA-seq data were aligned with STAR alignment (v2.4.2) and quantified using Salmon (v0.6.0). Differential gene expression analysis was performed using the R DESEq2 package. 49 Among all significantly expressed genes (FDR p≦0.05) between GD2.28ζ-CAR-T cells and GD2.28ζ+B7-H3.BB.CAR-T cells, expression was further filtered to obtain genes contained in IFN-γ and pathway signatures.
[0128] CAR-T cell activation for RNA-seq, qPCR, and cellular metabolic assays 1 mg / mL of 1A7 anti-idiotype mAb specific to 14G2a scFv and 1 μg / mL of 4Ig-B7-H3 (Chimerigen Laboratories) fused with mouse Fc were coated onto 24-well plates treated with non-tissue culture in a refrigerated room for 16 hours. After washing the plates three times with DPBS (Corning), T cells (1 × 10⁶) were added to the plates. 6 Cells were seeded (per well). CAR-T cells were incubated at 37°C for 24 hours on 1A7 mAb and 4Ig-B7-H3 coated plates. CAR-T cells were then transferred to 24-well tissue culture plates. T cell metabolism was measured using a Seahorse XFe24 analyzer (Seahorse Bioscience). 5 × 10⁶ cells were added to Seahorse BASE medium containing additives in the 24-well Seahorse XF-24 assay plates. 5 T cells were seeded. The cells were incubated at 37°C in a non-CO2 incubator for 45 minutes. All media were adjusted to pH 7.4 on the day of the assay. Mitochondrial and glycolysis stress tests were performed according to the manufacturer's protocol. Oxygen consumption rate and extracellular acidification rate were automatically calculated and recorded using Seahorse XF-24 software.
[0129] Confocal microscopy observation T cells expressing GFP-tagged GD2.28ζ CAR and B7-H3.BB CAR were stimulated with either an anti-14g2a idiotype antibody (1A7) or 2Ig-B7-H3 (R&D) fused with human IgG1-Fc, and then crosslinked with either a rat anti-mouse IgG1 secondary antibody (BD Biosciences) or an Alexa Fluor 647 conjugated goat anti-human IgG secondary antibody (Jackson ImmunoResearch Laboratories Inc.), respectively. For double CAR crosslinking, CAR-T cells were simultaneously stained with 1A7 and 2Ig-B7-H3-Fc, and then crosslinked with both of the corresponding secondary antibodies. All primary staining was performed at room temperature for 10 minutes, and secondary crosslinking was performed at 37°C for 15 minutes. Next, CAR-T cells were fixed with cytofix buffer (BD Biosciences), stained with DAPI (Invitrogen) according to the manufacturer's protocol, washed with PBS, and mounted on Glass Bottom Microwell Dishes (MatTek Corporation). Data was acquired using ZEN software (ZEISS Microscopy) with an LSM700 Zeiss laser scanning confocal microscope (63x objective lens / 1.4 Plan Apo Oil, pixel size 0.07 μm, pinhole size 1 AU). All image sets were acquired with the same settings. Data analysis was performed using Fiji software.
[0130] Xenotransplant mouse models Mouse experiments were conducted in accordance with the University of North Carolina (UNC) Animal Husbandry Guidelines and the protocol approved by the UNC Animal Experimentation Committee. Mice were maintained in a 12-hour day-to-12-hour night cycle under specific pathogen-free conditions, and their health was regularly monitored. Animals exhibiting clinically evident symptoms of disease (failure to eat, lack of activity, abnormal grooming behavior, hunched posture) or excessive weight loss (15% weight loss in one week) were euthanized. For these studies, 8-10 week old female NSG mice (NOD.Cg-Prkdc) were used. scid IL2rg tm1Wj12 × 10⁻¹⁰ via tail vein to / SzJ, UNC Animal Studies Core Facility) 6 FFLuc-CHLA-255, 4×10 6 FFLuc-LAN-1, 0.5×10 6 or 1 × 10 6 FFLuc-SH-SY5Y was administered intravenously. 7–14 days after tumor cell injection, 2 or 6 × 10⁶ doses were administered. 6 CAR-positive T cells were injected intravenously via the tail vein. For the mesothelioma intraperitoneal metastasis xenograft model, 3 × 10⁶ cells were used. 6 FFLuc-labeled H2052 cells were suspended in 50 μL of PBS, mixed with 50 μL of Matrigel (Corning), and implanted by intraperitoneal injection. Mice were then treated with CAR-T cells 12 days after tumor implantation by intraperitoneal injection. Tumor growth was monitored by bioluminescence imaging using the IVIS Lumina II in vivo imaging system (PerkinElmer) or the AMI Optical in vivo imaging system (Spectral instruments imaging). Blood was collected from mice at specific intervals (10–15 days, according to UNC-IACUC guidelines) to measure T cell frequency and / or phenotype. If signs of discomfort were detected by the researcher, or if the mouse was monitored three times a week on the recommendation of a veterinarian, or if the tumor bioluminescence signal was 10 10 Photon · s -1 If the maximum tumor load was exceeded, the mice were euthanized. None of the mice exceeded the maximum tumor load. At the time of euthanasia, blood and spleen were isolated and analyzed to detect CAR-T cells. In tumor re-administration experiments, 1 × 10⁶ CAR-T cells were administered to tumor-bearing mice via the tail vein. 6 The FFLuc-CHLA-255 cells were further injected intravenously.
[0131] statistical analysis As stated in the figure captions, data were summarized as mean + standard deviation. For multiple group comparisons, one-way analysis of variance (ANOVA) was used to determine statistical significance between groups. A p-value < 0.05 corrected by Tukey's multiple comparison test indicates statistical significance. Differences between two groups were determined by an unpaired two-sided t-test. A p-value < 0.05 indicates significance. Differences between survival curves were analyzed using the log-rank test with GraphPad Prism v8. The number of experimental samples (n) is shown in the figure caption. The aggregate analysis method is also described in the caption for each figure. Graph generation and statistical analysis were performed using GraphPad Prism software.
[0132] [ka] [ka] [ka] [ka] [ka] [ka]
Claims
1. Engineered T cells containing a dual-targeting CAR with a split costimulatory signal and a single CAR-CD3ζ domain.
2. The modified T cell of claim 1, which costimulates CD28 and 4-1BB.
3. The modified T cell of claim 1, which expresses GD2 and B7-H3.
4. The modified T cell of claim 1, which exhibits dual antigen specificity and costimulation.
5. 2. The modified T cell of claim 1, wherein the modified T cell exhibits T cell killing activity and cytokine release via GD2.28ζ.CAR or B7-H3.BB.CAR.
6. 2. The modified T cell of claim 1, which exhibits increased IFN-γ and IL-2 release compared to control cells.
7. The modified T cell of claim 1, which exhibits a higher basal level of TCR activation signaling compared to a control cell.
8. The modified T cell of claim 1, which exhibits enhanced phosphorylation of CAR-CD3 ζ chain and downstream signaling kinases.
9. The modified T cell of claim 8, wherein the downstream signaling kinases include ERK and Akt.
10. The modified T cell of claim 1, which exhibits enrichment in a cell cycle pathway.
11. The modified T cell of claim 1, which exhibits enrichment in the TCR signaling pathway.
12. The modified T cell of claim 1, which exhibits increased glycolytic activity compared to control cells.
13. The modified T cell of claim 1, which controls tumor growth upon tumor re-challenge relative to a control cell.
14. The modified T cell of claim 1, which promotes enhanced tumor control and improved survival compared to a control cell.
15. The modified T cell of claim 1, which exhibits increased anti-tumor activity.
16. The modified T cell of claim 15, which exhibits increased anti-tumor activity under stress conditions.
17. The modified T cell of claim 1 which is a human T cell.
18. The modified T cell of claim 1 , which is a non-human T cell.
19. The modified T cell of claim 17, which is a mouse T cell.
20. CD4 + and CD8 + The population of modified T cells of claim 1 which are T cells.
21. The modified T cells are + T cells and CD8 + Both CD27 on T cells + / CD29 + The population of claim 19, which is enriched in cells.
22. Modified T cells comprising GD2.28ζ.CAR / B7-H3.BB.CAR.
23. 1. A composition for treating cancer, comprising an engineered T cell comprising a dual-targeting CAR having a split costimulatory signal and a single CAR-CD3ζ domain, wherein the composition is administered to a subject.
24. The composition of claim 23, wherein the T cells costimulate CD28 and 4-1BB.
25. The composition of claim 23, wherein the T cells express GD2 and B7-H3.
26. 24. The composition of claim 23, wherein the modified T cells exhibit increased anti-tumor activity.
27. 24. The composition of claim 23, wherein the modified T cells protect against tumor rechallenge.
28. The composition of claim 23 , wherein the cancer is neuroblastoma.
29. The composition of claim 23 , wherein the subject is a mammal.
30. The composition of claim 23 , wherein the subject is a human.
